norfloxacin has been researched along with Urinary Tract Infections in 245 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
Urinary Tract Infections: Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A review of worldwide clinical trials with norfloxacin in the treatment of uncomplicated urinary tract infections (UTIs), as well as our personal experience with 215 assessable patients, is presented." | 10.16 | Review of norfloxacin in lower urinary tract infections. ( Gandolfi, P; Goldoni, S; Miano, L; Paradiso Galatioto, G; Tubaro, A, 1990) |
| "These data indicate that a 3 day treatment with ciprofloxacin is at least as clinically and bacteriologically effective as 7 day treatments with trimethoprim/sulfamethoxazole and norfloxacin for uncomplicated lower urinary tract infections." | 9.11 | Comparison of short-term treatment regimen of ciprofloxacin versus long-term treatment regimens of trimethoprim/sulfamethoxazole or norfloxacin for uncomplicated lower urinary tract infections: a randomized, multicentre, open-label, prospective study. ( Amábile-Cuevas, CF; Arredondo-García, JL; Cardeñosa-Guerra, O; Corral, M; Costa, A; Figueroa-Damián, R; Hernández-Oliva, GM; Jáuregui, A; Merlos, RM; Olguín, J; Ríos-Fabra, A; Rosas, A, 2004) |
| "The efficacy and tolerability of brodimoprim OD versus norfloxacin BID were studied in patients affected by bacterial urinary tract infections." | 9.08 | Efficacy and tolerability of brodimoprim od versus norfloxacin bid in the treatment of bacterial urinary tract infections. ( Cocuzza, C; Cogo, R; Demartini, G; Raschi, S; Scaglione, F, 1995) |
| "Norfloxacin 400 mg twice-a-day has proven to be effective and safe in the treatment of uncomplicated urinary tract infections (UTI)." | 9.08 | Efficacy and safety of norfloxacin 800 mg once-daily versus norfloxacin 400 mg twice-daily in the treatment of uncomplicated urinary tract infections in women: a double-blind, randomized clinical trial. ( Dolgner, A; Guimarães, J; Mário-Reis, J; Pimentel, FL; Quintas, M, 1998) |
| "The bacteriologic and clinical efficacies of 3 days of lomefloxacin therapy were compared with those of 3 days of norfloxacin therapy for the treatment of acute uncomplicated urinary tract infections in a prospective, randomized, double-blind study." | 9.07 | Treatment of acute uncomplicated urinary tract infections with 3 days of lomefloxacin compared with treatment with 3 days of norfloxacin. ( Conly, JM; DuBois, J; Harding, GK; Martel, AY; Nicolle, LE; Shafran, SD, 1993) |
| "Seventy patients with complicated urinary tract infections were treated with either lomefloxacin (400 mg once daily) or norfloxacin (400 mg twice daily) for 10 to 14 days." | 9.07 | Safety and efficacy of lomefloxacin versus norfloxacin in the treatment of complicated urinary tract infections. ( Benne, RA; Boon, TA; de Hond, HA; de Wit, MA; Havinga, WH; Hoepelman, IM; van Asbeck, FW; Verhoef, J; Visser, MR; Zwinkels, M, 1993) |
| "Fleroxacin, 400 mg once daily, and norfloxacin, 400 mg twice daily, both administered orally, were compared for the treatment of serious urinary tract infections (UTIs)." | 9.07 | Fleroxacin versus norfloxacin for oral treatment of serious urinary tract infections. ( Childs, SJ, 1993) |
| "The efficacy and safety of 7-10-day courses of lomefloxacin (single daily dose of 400 mg) or norfloxacin (twice-daily doses of 400 mg) for the treatment of uncomplicated urinary tract infections were compared in two large, multicenter, randomized trials." | 9.07 | Efficacy of lomefloxacin as compared to norfloxacin in the treatment of uncomplicated urinary tract infections in adults. ( Iravani, A, 1992) |
| "This randomised, double-blind, multicenter study compared the safety and efficacy of lomefloxacin and norfloxacin in adult female outpatients with uncomplicated urinary tract infections." | 9.07 | Lomefloxacin versus norfloxacin in the treatment of uncomplicated urinary tract infections: three-day versus seven-day treatment. The South Swedish Lolex Study Group. ( Forsgren, A; Hansson, C; Neringer, R; Ode, B, 1992) |
| " Its clinical efficacy and tolerability were compared with those of norfloxacin in patients with intercurrent urinary tract infections plus chronic liver diseases." | 9.07 | Cefodizime (HR221) versus norfloxacin for treatment of urinary tract infections. ( Basani, F; Esposito, S; Gaeta, GB; Galante, D; Giusti, G; Sardaro, C, 1991) |
| "One hundred thirty-eight patients with pyelonephritis were treated with norfloxacin, 400 mg twice daily." | 9.06 | Review of the efficacy of oral norfloxacin in pyelonephritis and nosocomial urinary tract infection. ( Corrado, ML; Lancaster, MS; Roylance, PJ; Struble, WE, 1990) |
| "In a controlled, randomized trial of 133 patients with proven urinary tract infections (UTIs), significantly more pathogens were found to be susceptible to norfloxacin than to trimethoprim-sulfamethoxazole (TMP-SMZ) (p less than 0." | 9.06 | Norfloxacin versus trimethoprim-sulfamethoxazole in the treatment of urinary tract infections. ( Bolding, OT; Brown, KR; Corrado, ML; Eng, RH; Harrison, L; Hesney, M; Landes, R; Ryan, J; Struble, WE, 1990) |
| "In a single-blind, randomized study of multicentre trial design 343 hospitalized geriatric patients (median age 83 years) suffering from symptomatic urinary tract infections (UTI) were treated with either norfloxacin 200 mg twice daily or pivmecillinam 200 mg 3 times daily orally for 7 days to compare the clinical efficacy and safety of the antibiotics in the elderly." | 9.06 | Norfloxacin vs. pivmecillinam in the treatment of uncomplicated lower urinary tract infections in hospitalized elderly patients. ( Englund, G; Jonsson, M; Nörgård, K, 1990) |
| "In a double-blind four-block randomized trial the efficacy and tolerance of a single dose of pefloxacin 800 mg was compared with a five day treatment with norfloxacin 400 mg twice daily in the treatment of uncomplicated urinary tract infections in general practice." | 9.06 | Single-dose pefloxacin versus five-days treatment with norfloxacin in uncomplicated cystitis in women. ( de Melker, RA; Touw-Otten, FW; van Balen, FA, 1990) |
| "Eighty-two evaluable patients suffering from UTI were randomly treated with parenteral Aztreonam (1 g OD in cystitis and 1 g BID in pyelonephritis) or oral Norfloxacin (400 mg BID)." | 9.06 | [Aztreonam vs norfloxacin: a comparative study of the treatment of urinary tract infections in ambulatory and hospitalized patients]. ( De Rose, AF; Germinale, F; Puppo, P, 1989) |
| "A double-blind controlled trial of norfloxacin versus cotrimoxazole in the treatment of urinary tract infections was conducted." | 9.06 | A double-blind controlled trial of norfloxacin versus cotrimoxazole in the treatment of urinary tract infections. ( Chan, MK; Cheng, IK; Wong, WT, 1989) |
| "The therapeutic efficacy and safety of norfloxacin 400 mg twice daily for 3 or 7 days was compared in a double-blind randomized multiclinic study including 485 female general practice patients with uncomplicated symptomatic lower urinary tract infections." | 9.06 | Double-blind comparison of 3-day versus 7-day treatment with norfloxacin in symptomatic urinary tract infections. The Inter-Nordic Urinary Tract Infection Study Group. ( , 1988) |
| "The study compared the efficacy and safety of norfloxacin to those of co-trimoxazole in the treatment of urinary tract infections (UTI)." | 9.06 | Treatment of urinary tract infections in Hong Kong: a comparative study of norfloxacin and co-trimoxazole. ( Chan, MK; Cheng, IK; Li, MK; Wong, WS; Wong, WT; Yin, PD, 1988) |
| "The clinical and bacteriological efficacy of norfloxacin and co-trimoxazole was compared in patients with symptomatic upper urinary tract infections (UTI)." | 9.06 | Norfloxacin versus co-trimoxazole for the treatment of upper urinary tract infections: a double blind trial. ( Chongthaleong, A; Petcharabutr, OA; Sitprija, V; Tungsanga, K; Udomsantisuk, N; Wong, EC, 1988) |
| "In a multicenter, prospective treatment study, 59 patients with complicated or uncomplicated urinary tract infections (UTIs) were treated with norfloxacin (400 mg orally twice daily) and compared with 45 patients treated with trimethoprim/sulfamethoxazole." | 9.06 | Norfloxacin in the treatment of complicated and uncomplicated urinary tract infections. A comparative multicenter trial. ( Alpert, ML; Cherubin, CE; Eng, RH; Ginsburg, BP; Goldstein, EJ; Kahn, RM; Najem, A, 1987) |
| "A retrospective analysis of data from the treatment of 95 men with nonbacteremic urinary tract infections (UTIs) (clean-catch urinary bacterial count greater than or equal to 10(5) colony-forming units/ml) who received norfloxacin (400 mg orally twice daily) was performed." | 9.06 | Norfloxacin in the treatment of urinary tract infections in men with and without identifiable urologic complications. ( Corrado, ML; Grad, C; Sabbaj, J, 1987) |
| "Two-hundred nine patients with symptoms of acute urinary tract infection and pyuria were randomized to 400 mg of administered norfloxacin twice daily for three days, or 800 mg of sulfamethoxazole and 160 mg of trimethoprim administered twice daily for ten days." | 9.06 | A multicenter comparative trial of three-day norfloxacin vs ten-day sulfamethoxazole and trimethoprim for the treatment of uncomplicated urinary tract infections. ( Boyko, EJ; Cox, CE; Goldstein, EJ; Kurtz, TO; Miller, K; Mummaw, N; Reller, LB; Stein, GE, 1987) |
| "The efficacies of ofloxacin and norfloxacin in the treatment of chronic complicated urinary tract infections were compared." | 9.06 | Open randomised comparison of ofloxacin and norfloxacin in the treatment of complicated urinary tract infections. ( Rugendorff, EW, 1987) |
| "Norfloxacin (NOR) was compared to pipemidic acid (PA) in complicated urinary tract infections (UTIs) caused by pathogens susceptible to both agents to evaluate the antibacterial activity of the new 4-quinolone derivative." | 9.06 | Norfloxacin versus pipemidic acid in complicated urinary tract infections due to susceptible pathogens: a comparative clinical trial. ( Boldrini, F; Del Favero, A; Frongillo, RF; Guerciolini, R; Menichetti, F; Pauluzzi, S, 1986) |
| "Forty patients with urinary tract infections were randomly assigned to receive a ten-day course of oral therapy with either norfloxacin 400 mg twice daily or cotrimoxazole (trimethoprim-sulfamethoxazole) 160/800 mg twice daily." | 9.05 | Clinical evaluation of norfloxacin versus cotrimoxazole in urinary tract infections. ( Antunez de Mayolo, E; Benavente, L; Falconi, E; Guerra, JG; Palomino, JC, 1983) |
| "One hundred and twenty-two patients with uncomplicated urinary tract infections were treated with either 400 mg bd norfloxacin or 160/800 mg bd cotrimoxazole for 7 days." | 9.05 | Norfloxacin versus cotrimoxazole in the treatment of uncomplicated urinary tract infections--a multi-centre trial. ( Chait, I; Deaney, NB; Kelsey, MC; Newsom, RA; Newsom, SW; Round, EM; Smith, J; Toase, PD; Vogel, R; Watt, B, 1984) |
| "Forty-three women with acute, symptomatic urinary tract infections were randomized to receive either norfloxacin (400 mg) twice daily or trimethoprim-sulfamethoxazole (160-800 mg) twice daily for 10 days." | 9.05 | Comparative trial of norfloxacin and trimethoprim-sulfamethoxazole in the treatment of women with localized, acute, symptomatic urinary tract infections and antimicrobial effect on periurethral and fecal microflora. ( Haase, DA; Harding, GK; Kennedy, JK; Ronald, AR; Thomson, MJ; Urias, BA, 1984) |
| "In a prospective, randomized trial, norfloxacin (400 mg perorally, twice a day) was compared with trimethoprim-sulfamethoxazole (160-800 mg perorally, twice a day) in 45 patients with uncomplicated urinary tract infections." | 9.05 | Norfloxacin versus trimethoprim-sulfamethoxazole in the therapy of uncomplicated, community-acquired urinary tract infections. ( Alpert, ML; Ginsberg, BP; Goldstein, EJ, 1985) |
| " No significant differences in prophylactic antibiotic treatment with nitrofurantoin and norfloxacin, trimethoprim, sulfamethoxazole/trimethoprim, methamine hippurate, estriol, or cefaclor were found in clinical or microbiological cure in adult nonpregnant women with recurrent urinary tract infections (9 randomized control trials, 673 patients, relative risk ratio, 1." | 8.93 | Nitrofurantoin vs other prophylactic agents in reducing recurrent urinary tract infections in adult women: a systematic review and meta-analysis. ( Gregory, WT; Guran, LA; McDonagh, MS; Price, JR, 2016) |
| "Nitroxoline, a hydroxychinoline derivate, has been used for many years to treat urinary tract infections (UTI)." | 8.90 | Review of the literature and individual patients' data meta-analysis on efficacy and tolerance of nitroxoline in the treatment of uncomplicated urinary tract infections. ( Naber, KG; Niggemann, H; Stein, G, 2014) |
| "In seven studies of complicated and recurrent urinary tract infections, 285 patients were treated with norfloxacin 400 mg b." | 8.78 | Review of norfloxacin in complicated and recurrent urinary tract infections. ( Schaeffer, AJ, 1990) |
| "The antibiotic nitrofurantoin is commonly used to treat uncomplicated urinary tract infections." | 7.81 | Kidney function and the use of nitrofurantoin to treat urinary tract infections in older women. ( Gandhi, S; Garg, AX; Jain, AK; Liu, AR; McArthur, E; Moist, L; Singh, N; Sood, MM, 2015) |
| "The authors report on a case of tamoxifen/norfloxacin interaction leading to QT interval prolongation in an 83-year-old female patient with extracranial meningioma treated with radiation and hormonal therapy (with Tamoxifen)." | 7.77 | Tamoxifen/norfloxacin interaction leading to QT interval prolongation in a female patient with extracranial meningioma. ( Kopecky, J; Petera, J; Priester, P; Slanska, I; Slovacek, L, 2011) |
| "Ninety-nine patients with simple symptomatic urinary tract infections from three general practices were treated with norfloxacin 400 mg bd for 3 days and were followed up for 2 to 4 weeks." | 7.67 | Treatment of simple urinary tract infections in general practice with a 3-day course of norfloxacin. ( Kirby, CP, 1984) |
| "The effects on the long-term use of norfloxacin, a fluorinated 4-quinolone, on the intestinal flora (both aerobic and anaerobic), were evaluated in patients suffering from recurrent complicated urinary tract infections." | 7.67 | Effects of norfloxacin on the faecal flora in patients with complicated urinary tract infections. ( Boerema, JB; Olthof, BJ; van Saene, HK, 1986) |
| "One hundred and four patients with complicated urinary tract infections (prolonged severe chronic infections or with complicated postoperative conditions) were treated for ten days with pefloxacin 400 mg bid." | 7.67 | Efficacy and safety of pefloxacin in the treatment of patients with complicated urinary tract infections. ( Boerema, JB; Crombach, W; Pauwels, R; Scheepers, J, 1986) |
| "28 patients with urinary tract infections (UTI) were treated with norfloxacin 2 X 400 mg daily for 9 days." | 7.67 | [Norfloxacin in the treatment of urinary tract infections]. ( Joost, J, 1986) |
| "The clinical effectiveness and safety of norfloxacin were evaluated in 34 patients with urinary tract infections." | 7.67 | [Clinical studies of norfloxacin in urinary tract infections]. ( Kurita, T; Matsuura, T, 1985) |
| "Temafloxacin is a new oral fluoroquinolone with broad-spectrum antimicrobial activity against gram-negative and gram-positive pathogens." | 6.67 | Oral temafloxacin compared to norfloxacin for the treatment of complicated urinary tract infections. ( Cox, CE, 1991) |
| " The simplified dosage regimen (single dose) and its favorable benefit/risk ratio justifies the use of Fosfomycin trometamol as a treatment for uncomplicated urinary tract infections in female patients." | 6.67 | Single-dose fosfomycin trometamol (Monuril) versus multiple-dose norfloxacin: results of a multicenter study in females with uncomplicated lower urinary tract infections. ( de Jong, Z; Plante, P; Pontonnier, F, 1991) |
| " The 200-mg dosage of norfloxacin seemed to cause fewer side effects than the 400-mg dosage." | 6.66 | Coordinated multicenter study of norfloxacin versus trimethoprim-sulfamethoxazole treatment of symptomatic urinary tract infections. The Urinary Tract Infection Study Group. ( , 1987) |
| "treatment with norfloxacin 200 mg or 400 mg or trimethoprim/sulfamethoxazole." | 6.66 | Norfloxacin versus co-trimoxazole for treatment of urinary tract infections in adults: microbiological results of a coordinated multicentre study. ( Norrby, SR; Rylander, M; Svärd, R, 1987) |
| "Norfloxacin is a lipid-soluble weak organic acid bound to plasma proteins to a low extent." | 6.66 | Norfloxacin versus co-trimoxazole in the treatment of recurring urinary tract infections in men. ( Cook, T; Hoagland, VL; Sabbaj, J, 1986) |
| "Norfloxacin was as effective in eradicating bacteriuria as amoxycillin, cotrimoxazole or citrated nalidixic acid." | 6.65 | Norfloxacin, amoxycillin, cotrimoxazole and nalidixic acid. A summary of 3-day and 7-day therapy studies in the treatment of urinary tract infections. ( Currie, WJ; Deaney, NB; Round, EM; VandenBurg, MJ; Vogel, R, 1984) |
| "Norfloxacin is a valuable addition to the oral antimicrobial agents available for the treatment of urinary tract infection." | 6.65 | Comparative study using norfloxacin and amoxycillin in the treatment of complicated urinary tract infections in geriatric patients. ( Leigh, DA; Marriner, J; Smith, EC, 1984) |
| "Norfloxacin (MK-0366) is a new antibacterial agent, closely related to nalidixic acid, with broad spectrum activity against Gram-positive and Gram-negative organisms, including Pseudomonas aeruginosa." | 5.27 | Norfloxacin (MK-0366) treatment of urinary tract infections in hospitalized patients. ( Panichi, G; Pantosti, A; Testore, GP, 1983) |
| "were treated with norfloxacin and 16 (84%) responded to therapy." | 5.27 | The treatment of Pseudomonas aeruginosa urinary tract infections with norfloxacin. ( Emmanuel, FX; Leigh, DA, 1984) |
| "Women with recurrent urinary tract infections received a dip slide urine culture kit and 6 tablets of norfloxacin (400 mg." | 5.09 | Efficacy and safety of self-start therapy in women with recurrent urinary tract infections. ( Schaeffer, AJ; Stuppy, BA, 1999) |
| "The efficacy and tolerability of brodimoprim OD versus norfloxacin BID were studied in patients affected by bacterial urinary tract infections." | 5.08 | Efficacy and tolerability of brodimoprim od versus norfloxacin bid in the treatment of bacterial urinary tract infections. ( Cocuzza, C; Cogo, R; Demartini, G; Raschi, S; Scaglione, F, 1995) |
| "The bacteriologic and clinical efficacies of 3 days of lomefloxacin therapy were compared with those of 3 days of norfloxacin therapy for the treatment of acute uncomplicated urinary tract infections in a prospective, randomized, double-blind study." | 5.07 | Treatment of acute uncomplicated urinary tract infections with 3 days of lomefloxacin compared with treatment with 3 days of norfloxacin. ( Conly, JM; DuBois, J; Harding, GK; Martel, AY; Nicolle, LE; Shafran, SD, 1993) |
| "Seventy patients with complicated urinary tract infections were treated with either lomefloxacin (400 mg once daily) or norfloxacin (400 mg twice daily) for 10 to 14 days." | 5.07 | Safety and efficacy of lomefloxacin versus norfloxacin in the treatment of complicated urinary tract infections. ( Benne, RA; Boon, TA; de Hond, HA; de Wit, MA; Havinga, WH; Hoepelman, IM; van Asbeck, FW; Verhoef, J; Visser, MR; Zwinkels, M, 1993) |
| "A total of 125 ambulatory women (85 premenopausal and 40 postmenopausal) who experienced 174 acute urinary tract infections with mainly gram-negative bacteria (99%) was randomized to receive a single dose, 2-tablet treatment with either ofloxacin (400 mg." | 5.07 | Single dose quinolone treatment in acute uncomplicated urinary tract infection in women. ( Pfau, A; Sacks, TG, 1993) |
| "Fleroxacin, 400 mg once daily, and norfloxacin, 400 mg twice daily, both administered orally, were compared for the treatment of serious urinary tract infections (UTIs)." | 5.07 | Fleroxacin versus norfloxacin for oral treatment of serious urinary tract infections. ( Childs, SJ, 1993) |
| "The efficacy and safety of 7-10-day courses of lomefloxacin (single daily dose of 400 mg) or norfloxacin (twice-daily doses of 400 mg) for the treatment of uncomplicated urinary tract infections were compared in two large, multicenter, randomized trials." | 5.07 | Efficacy of lomefloxacin as compared to norfloxacin in the treatment of uncomplicated urinary tract infections in adults. ( Iravani, A, 1992) |
| "This randomised, double-blind, multicenter study compared the safety and efficacy of lomefloxacin and norfloxacin in adult female outpatients with uncomplicated urinary tract infections." | 5.07 | Lomefloxacin versus norfloxacin in the treatment of uncomplicated urinary tract infections: three-day versus seven-day treatment. The South Swedish Lolex Study Group. ( Forsgren, A; Hansson, C; Neringer, R; Ode, B, 1992) |
| "A total of 102 women with recurrent urinary tract infections were included in this open randomized study; 55 received 200 mg of norfloxacin daily and 47 received 50 mg of nitrofurantoin daily over 6 months." | 5.07 | Long-term prophylaxis with norfloxacin versus nitrofurantoin in women with recurrent urinary tract infection. ( Boger, S; Raz, R, 1991) |
| " Its clinical efficacy and tolerability were compared with those of norfloxacin in patients with intercurrent urinary tract infections plus chronic liver diseases." | 5.07 | Cefodizime (HR221) versus norfloxacin for treatment of urinary tract infections. ( Basani, F; Esposito, S; Gaeta, GB; Galante, D; Giusti, G; Sardaro, C, 1991) |
| "One hundred thirty-eight patients with pyelonephritis were treated with norfloxacin, 400 mg twice daily." | 5.06 | Review of the efficacy of oral norfloxacin in pyelonephritis and nosocomial urinary tract infection. ( Corrado, ML; Lancaster, MS; Roylance, PJ; Struble, WE, 1990) |
| "In a controlled, randomized trial of 133 patients with proven urinary tract infections (UTIs), significantly more pathogens were found to be susceptible to norfloxacin than to trimethoprim-sulfamethoxazole (TMP-SMZ) (p less than 0." | 5.06 | Norfloxacin versus trimethoprim-sulfamethoxazole in the treatment of urinary tract infections. ( Bolding, OT; Brown, KR; Corrado, ML; Eng, RH; Harrison, L; Hesney, M; Landes, R; Ryan, J; Struble, WE, 1990) |
| "In a single-blind, randomized study of multicentre trial design 343 hospitalized geriatric patients (median age 83 years) suffering from symptomatic urinary tract infections (UTI) were treated with either norfloxacin 200 mg twice daily or pivmecillinam 200 mg 3 times daily orally for 7 days to compare the clinical efficacy and safety of the antibiotics in the elderly." | 5.06 | Norfloxacin vs. pivmecillinam in the treatment of uncomplicated lower urinary tract infections in hospitalized elderly patients. ( Englund, G; Jonsson, M; Nörgård, K, 1990) |
| "In a double-blind four-block randomized trial the efficacy and tolerance of a single dose of pefloxacin 800 mg was compared with a five day treatment with norfloxacin 400 mg twice daily in the treatment of uncomplicated urinary tract infections in general practice." | 5.06 | Single-dose pefloxacin versus five-days treatment with norfloxacin in uncomplicated cystitis in women. ( de Melker, RA; Touw-Otten, FW; van Balen, FA, 1990) |
| "The aim of this study was to carry out a small-scale bacteriological comparison between a standard therapy with norfloxacin 400 mg twice daily, and fosfomycin trometamol (3 g) in single dose in uncomplicated urinary tract infections (UTI) in women." | 5.06 | Single dose fosfomycin trometamol versus multiple dose norfloxacin over three days for uncomplicated UTI in general practice. ( Reynaert, J; Van Eyck, D; Vandepitte, J, 1990) |
| "Norfloxacin, a broad-spectrum antimicrobial analog of nalidixic acid, was evaluated by comparing it to trimethoprim-sulfamethoxazole in 93 office patients with recurrent urinary tract infections." | 5.06 | Treatment of recurrent urinary tract infection with norfloxacin versus trimethoprim-sulfamethoxazole. ( Amy, BG; Childs, SJ; Hurst, AT; Krisch, EB; McCabe, RE; Seidmon, EJ; Truant, AL, 1990) |
| "Eighty-two evaluable patients suffering from UTI were randomly treated with parenteral Aztreonam (1 g OD in cystitis and 1 g BID in pyelonephritis) or oral Norfloxacin (400 mg BID)." | 5.06 | [Aztreonam vs norfloxacin: a comparative study of the treatment of urinary tract infections in ambulatory and hospitalized patients]. ( De Rose, AF; Germinale, F; Puppo, P, 1989) |
| "A randomized clinical study was conducted in order to compare the effectiveness of norfloxacin and cinoxacin in complicated urinary tract infections." | 5.06 | [Comparative evaluation of norfloxacin and cinoxacin in the therapy of complicated infections of the urinary tract]. ( Cristiano, P; Della Vittoria Scarpati, M; Iovene, MR; Manguso, L; Morelli, G; Simioli, F, 1989) |
| "A double-blind controlled trial of norfloxacin versus cotrimoxazole in the treatment of urinary tract infections was conducted." | 5.06 | A double-blind controlled trial of norfloxacin versus cotrimoxazole in the treatment of urinary tract infections. ( Chan, MK; Cheng, IK; Wong, WT, 1989) |
| "The therapeutic efficacy and safety of norfloxacin 400 mg twice daily for 3 or 7 days was compared in a double-blind randomized multiclinic study including 485 female general practice patients with uncomplicated symptomatic lower urinary tract infections." | 5.06 | Double-blind comparison of 3-day versus 7-day treatment with norfloxacin in symptomatic urinary tract infections. The Inter-Nordic Urinary Tract Infection Study Group. ( , 1988) |
| "The study compared the efficacy and safety of norfloxacin to those of co-trimoxazole in the treatment of urinary tract infections (UTI)." | 5.06 | Treatment of urinary tract infections in Hong Kong: a comparative study of norfloxacin and co-trimoxazole. ( Chan, MK; Cheng, IK; Li, MK; Wong, WS; Wong, WT; Yin, PD, 1988) |
| "The clinical and bacteriological efficacy of norfloxacin and co-trimoxazole was compared in patients with symptomatic upper urinary tract infections (UTI)." | 5.06 | Norfloxacin versus co-trimoxazole for the treatment of upper urinary tract infections: a double blind trial. ( Chongthaleong, A; Petcharabutr, OA; Sitprija, V; Tungsanga, K; Udomsantisuk, N; Wong, EC, 1988) |
| "In a multiclinic, randomized trial, oral norfloxacin, a fluoroquinolone antibacterial, was compared with several standard parenteral regimens for the treatment of nonbacteremic, hospital-acquired urinary tract infections." | 5.06 | Oral norfloxacin versus parenteral treatment of nosocomial urinary tract infection. ( Cox, CE; Grad, C; McCabe, RE, 1987) |
| "In a multicenter, prospective treatment study, 59 patients with complicated or uncomplicated urinary tract infections (UTIs) were treated with norfloxacin (400 mg orally twice daily) and compared with 45 patients treated with trimethoprim/sulfamethoxazole." | 5.06 | Norfloxacin in the treatment of complicated and uncomplicated urinary tract infections. A comparative multicenter trial. ( Alpert, ML; Cherubin, CE; Eng, RH; Ginsburg, BP; Goldstein, EJ; Kahn, RM; Najem, A, 1987) |
| "A retrospective analysis of data from the treatment of 95 men with nonbacteremic urinary tract infections (UTIs) (clean-catch urinary bacterial count greater than or equal to 10(5) colony-forming units/ml) who received norfloxacin (400 mg orally twice daily) was performed." | 5.06 | Norfloxacin in the treatment of urinary tract infections in men with and without identifiable urologic complications. ( Corrado, ML; Grad, C; Sabbaj, J, 1987) |
| "Two-hundred nine patients with symptoms of acute urinary tract infection and pyuria were randomized to 400 mg of administered norfloxacin twice daily for three days, or 800 mg of sulfamethoxazole and 160 mg of trimethoprim administered twice daily for ten days." | 5.06 | A multicenter comparative trial of three-day norfloxacin vs ten-day sulfamethoxazole and trimethoprim for the treatment of uncomplicated urinary tract infections. ( Boyko, EJ; Cox, CE; Goldstein, EJ; Kurtz, TO; Miller, K; Mummaw, N; Reller, LB; Stein, GE, 1987) |
| "The efficacies of ofloxacin and norfloxacin in the treatment of chronic complicated urinary tract infections were compared." | 5.06 | Open randomised comparison of ofloxacin and norfloxacin in the treatment of complicated urinary tract infections. ( Rugendorff, EW, 1987) |
| "Forty patients with urinary tract infections were randomly assigned to receive a ten-day course of oral therapy with either norfloxacin 400 mg twice daily or cotrimoxazole (trimethoprim-sulfamethoxazole) 160/800 mg twice daily." | 5.05 | Clinical evaluation of norfloxacin versus cotrimoxazole in urinary tract infections. ( Antunez de Mayolo, E; Benavente, L; Falconi, E; Guerra, JG; Palomino, JC, 1983) |
| "One hundred and twenty-two patients with uncomplicated urinary tract infections were treated with either 400 mg bd norfloxacin or 160/800 mg bd cotrimoxazole for 7 days." | 5.05 | Norfloxacin versus cotrimoxazole in the treatment of uncomplicated urinary tract infections--a multi-centre trial. ( Chait, I; Deaney, NB; Kelsey, MC; Newsom, RA; Newsom, SW; Round, EM; Smith, J; Toase, PD; Vogel, R; Watt, B, 1984) |
| "Forty-three women with acute, symptomatic urinary tract infections were randomized to receive either norfloxacin (400 mg) twice daily or trimethoprim-sulfamethoxazole (160-800 mg) twice daily for 10 days." | 5.05 | Comparative trial of norfloxacin and trimethoprim-sulfamethoxazole in the treatment of women with localized, acute, symptomatic urinary tract infections and antimicrobial effect on periurethral and fecal microflora. ( Haase, DA; Harding, GK; Kennedy, JK; Ronald, AR; Thomson, MJ; Urias, BA, 1984) |
| "In a prospective, randomized trial, norfloxacin (400 mg perorally, twice a day) was compared with trimethoprim-sulfamethoxazole (160-800 mg perorally, twice a day) in 45 patients with uncomplicated urinary tract infections." | 5.05 | Norfloxacin versus trimethoprim-sulfamethoxazole in the therapy of uncomplicated, community-acquired urinary tract infections. ( Alpert, ML; Ginsberg, BP; Goldstein, EJ, 1985) |
| " No significant differences in prophylactic antibiotic treatment with nitrofurantoin and norfloxacin, trimethoprim, sulfamethoxazole/trimethoprim, methamine hippurate, estriol, or cefaclor were found in clinical or microbiological cure in adult nonpregnant women with recurrent urinary tract infections (9 randomized control trials, 673 patients, relative risk ratio, 1." | 4.93 | Nitrofurantoin vs other prophylactic agents in reducing recurrent urinary tract infections in adult women: a systematic review and meta-analysis. ( Gregory, WT; Guran, LA; McDonagh, MS; Price, JR, 2016) |
| "Nitroxoline, a hydroxychinoline derivate, has been used for many years to treat urinary tract infections (UTI)." | 4.90 | Review of the literature and individual patients' data meta-analysis on efficacy and tolerance of nitroxoline in the treatment of uncomplicated urinary tract infections. ( Naber, KG; Niggemann, H; Stein, G, 2014) |
| " For primary prophylaxis, short-term antibiotic treatment (oral norfloxacin or ciprofloxacin) is indicated in cirrhotic patients (with or without ascites) admitted with gastrointestinal haemorrhage (variceal or non-variceal)." | 4.84 | [Bacterial infections in liver cirrhosis]. ( Farkas, A; Papp, M; Tornai, I; Udvardy, M, 2007) |
| "The clinical and bacteriological activity of fosfomycin trometamol (FT) has been compared with several other antibiotics in the treatment of uncomplicated urinary tract infections." | 4.82 | Short term therapy for uncomplicated urinary tract infection today. Clinical outcome upholds the theories. ( Lobel, B, 2003) |
| "In seven studies of complicated and recurrent urinary tract infections, 285 patients were treated with norfloxacin 400 mg b." | 4.78 | Review of norfloxacin in complicated and recurrent urinary tract infections. ( Schaeffer, AJ, 1990) |
| "The antibiotic nitrofurantoin is commonly used to treat uncomplicated urinary tract infections." | 3.81 | Kidney function and the use of nitrofurantoin to treat urinary tract infections in older women. ( Gandhi, S; Garg, AX; Jain, AK; Liu, AR; McArthur, E; Moist, L; Singh, N; Sood, MM, 2015) |
| "The authors report on a case of tamoxifen/norfloxacin interaction leading to QT interval prolongation in an 83-year-old female patient with extracranial meningioma treated with radiation and hormonal therapy (with Tamoxifen)." | 3.77 | Tamoxifen/norfloxacin interaction leading to QT interval prolongation in a female patient with extracranial meningioma. ( Kopecky, J; Petera, J; Priester, P; Slanska, I; Slovacek, L, 2011) |
| "Norfloxacin is a quinoline (quinolinecarboxylic acid) that should prove successful in treating infections that currently require hospitalization and intravenous antibiotics." | 3.76 | Norfloxacin: a quinoline antibiotic. ( Bosso, JA; Marble, DA, 1986) |
| "or t." | 3.76 | World-wide clinical experience with norfloxacin: efficacy and safety. ( Corrado, M; Hoagland, V; Sabbaj, J; Wang, C, 1986) |
| "Norfloxacin-releasing urethral catheters were prepared for the purpose of preventing urinary tract infections during long-term catheterization." | 3.72 | Norfloxacin-releasing urethral catheter for long-term catheterization. ( Bae, YH; Cho, YH; Cho, YW; Choi, JM; Chung, H; Jeong, SY; Kwon, IC; Park, JH; Shin, HJ, 2003) |
| "We studied gastrointestinal (GI) colonization by Candida albicans in patients receiving oral norfloxacin, ciprofloxacin or ofloxacin as monotherapy for urinary tract infections." | 3.71 | The impact of norfloxacin, ciprofloxacin and ofloxacin on human gut colonization by Candida albicans. ( Cranidis, A; Kontoyiannis, DP; Maraki, S; Mavromanolakis, E; Samonis, G; Tselentis, Y, 2001) |
| "In continuous surveillance of routine samples from five Dutch laboratories, we studied resistance to the antibiotics most commonly prescribed for urinary tract infections (UTI) in The Netherlands, namely norfloxacin, amoxycillin, trimethoprim and nitrofurantoin, from 1989 to 1998 in >90000 Escherichia coli isolates." | 3.70 | Increasing resistance to fluoroquinolones in escherichia coli from urinary tract infections in the netherlands. ( Buiting, AG; de Neeling, AJ; Goettsch, W; Hendrix, MG; Nagelkerke, N; Petit, PL; Sabbe, LJ; van Griethuysen, AJ; van Pelt, W, 2000) |
| "Twenty-eight strains of Pseudomonas aeruginosa with various degrees of norfloxacin resistance were isolated from patients with urinary tract infections." | 3.69 | Mechanisms of high-level resistance to quinolones in urinary tract isolates of Pseudomonas aeruginosa. ( Iyobe, S; Mitsuhashi, S; Muratani, T; Yoshida, T, 1994) |
| "Because of increasing norfloxacin use and the development of resistant organisms, an evaluation was undertaken in a University Hospital to assess the appropriateness of norfloxacin for the treatment of urinary tract infections and to calculate the potential cost savings associated with more cost-effective antibiotic therapy." | 3.68 | The use of norfloxacin in a university hospital. ( Alaniz, C; Stumpf, JL; Townsend, KA, 1991) |
| "One hundred thirty-one patients of urologists and infectious disease specialists were entered into an open trial of norfloxacin in the therapy of urinary tract infections (UTIs)." | 3.68 | Norfloxacin use in urinary tract infection by urologists and infectious disease specialists. ( Berman, S; Goldstein, EJ; Harrison, L; Iannini, PB; Kunkel, MJ; Landes, R; Schaeffer, AJ; Snow, R; Wells, G, 1990) |
| "Ninety-nine patients with simple symptomatic urinary tract infections from three general practices were treated with norfloxacin 400 mg bd for 3 days and were followed up for 2 to 4 weeks." | 3.67 | Treatment of simple urinary tract infections in general practice with a 3-day course of norfloxacin. ( Kirby, CP, 1984) |
| "The effects on the long-term use of norfloxacin, a fluorinated 4-quinolone, on the intestinal flora (both aerobic and anaerobic), were evaluated in patients suffering from recurrent complicated urinary tract infections." | 3.67 | Effects of norfloxacin on the faecal flora in patients with complicated urinary tract infections. ( Boerema, JB; Olthof, BJ; van Saene, HK, 1986) |
| " Among quinolones, the most active agents are ciprofloxacin and ofloxacin (MIC modes: 4 and 2 mg/l), so these antimicrobials could be used for the treatment of urinary tract infections caused by Corynebacterium group D2." | 3.67 | [Corynebacterium group D2. Clinical study, biochemical identification and antibiotic sensitivity]. ( Cancet, B; Clave, D; Didier, J; Henry-Ferry, S; Marty, N, 1988) |
| "Eight patients aged over 65 years (mean age 81 years), with microbiologically proven urinary tract infections were treated with 400 mg norfloxacin bd daily for six days." | 3.67 | The pharmacokinetics of norfloxacin in the aged. ( Clarke, EA; Greig, MA; MacGowan, AP; Reeves, DS; White, LO, 1988) |
| " Norfloxacin was administered as two daily 400 mg oral doses to eight elderly patients requiring treatment for urinary tract infections." | 3.67 | Chronic dose urinary and serum pharmacokinetics of norfloxacin in the elderly. ( Deaney, NB; Kelly, JG; Lavan, J; Noel, J, 1988) |
| "Following a summary of the main bacteriological and pharmacokinetic properties of this new quinolone derivative, the author reviews the results obtained with pefloxacine in the treatment of urinary tract infection, gonococcal urethritis, and bronchopulmonary, surgical, gynaecological, bone, soft tissue, neuromeningeal and ENT infections." | 3.67 | [Pefloxacin: evaluation and clinical prospects]. ( Modaï, J, 1986) |
| "Twenty-four patients with complicated urinary tract infections were treated with norfloxacin for three months." | 3.67 | Norfloxacin treatment in complicated urinary tract infection. ( Boerema, JB; van Saene, HK, 1986) |
| "One hundred and four patients with complicated urinary tract infections (prolonged severe chronic infections or with complicated postoperative conditions) were treated for ten days with pefloxacin 400 mg bid." | 3.67 | Efficacy and safety of pefloxacin in the treatment of patients with complicated urinary tract infections. ( Boerema, JB; Crombach, W; Pauwels, R; Scheepers, J, 1986) |
| "28 patients with urinary tract infections (UTI) were treated with norfloxacin 2 X 400 mg daily for 9 days." | 3.67 | [Norfloxacin in the treatment of urinary tract infections]. ( Joost, J, 1986) |
| "The present study was carried out with the aim of comparing the microbiological and clinical efficacy of norfloxacin, cinoxacin and aztreonam in urinary tract infections." | 3.67 | Treatment of urinary infections: clinical perspectives. ( Carlone, NA; Fontana, G; Laudi, M; Savoia, D, 1987) |
| "Norfloxacin (NFLX) was administered to outpatients and inpatients with urinary tract infections at our department." | 3.67 | [Clinical experience of norfloxacin in urinary tract infection]. ( Abe, T; Aoki, H; Banya, Y; Funaki, H; Kubo, T; Ohori, T; Takagane, H; Tanji, S, 1985) |
| "The clinical effectiveness and safety of norfloxacin were evaluated in 34 patients with urinary tract infections." | 3.67 | [Clinical studies of norfloxacin in urinary tract infections]. ( Kurita, T; Matsuura, T, 1985) |
| "Norfloxacin treatment was associated with a persistent decrease in gram-negative isolates (p < 0." | 2.68 | Use of norfloxacin for prevention of symptomatic urinary tract infection in chronically catheterized patients. ( Rutschmann, OT; Zwahlen, A, 1995) |
| "Temafloxacin is a new oral fluoroquinolone with broad-spectrum antimicrobial activity against gram-negative and gram-positive pathogens." | 2.67 | Oral temafloxacin compared to norfloxacin for the treatment of complicated urinary tract infections. ( Cox, CE, 1991) |
| " The 200-mg dosage of norfloxacin seemed to cause fewer side effects than the 400-mg dosage." | 2.66 | Coordinated multicenter study of norfloxacin versus trimethoprim-sulfamethoxazole treatment of symptomatic urinary tract infections. The Urinary Tract Infection Study Group. ( , 1987) |
| "treatment with norfloxacin 200 mg or 400 mg or trimethoprim/sulfamethoxazole." | 2.66 | Norfloxacin versus co-trimoxazole for treatment of urinary tract infections in adults: microbiological results of a coordinated multicentre study. ( Norrby, SR; Rylander, M; Svärd, R, 1987) |
| "Norfloxacin is a lipid-soluble weak organic acid bound to plasma proteins to a low extent." | 2.66 | Norfloxacin versus co-trimoxazole in the treatment of recurring urinary tract infections in men. ( Cook, T; Hoagland, VL; Sabbaj, J, 1986) |
| "Norfloxacin was as effective in eradicating bacteriuria as amoxycillin, cotrimoxazole or citrated nalidixic acid." | 2.65 | Norfloxacin, amoxycillin, cotrimoxazole and nalidixic acid. A summary of 3-day and 7-day therapy studies in the treatment of urinary tract infections. ( Currie, WJ; Deaney, NB; Round, EM; VandenBurg, MJ; Vogel, R, 1984) |
| "Norfloxacin is a valuable addition to the oral antimicrobial agents available for the treatment of urinary tract infection." | 2.65 | Comparative study using norfloxacin and amoxycillin in the treatment of complicated urinary tract infections in geriatric patients. ( Leigh, DA; Marriner, J; Smith, EC, 1984) |
| " Many of the fluoroquinolone agents have once-daily dosing regimens, enhancing patient adherence." | 2.41 | The expanding role of fluoroquinolones. ( Schaeffer, AJ, 2002) |
| "Bacteriuria is much more common in the elderly than in younger individuals for a variety of reasons." | 2.37 | A review of urinary tract infection in the elderly. ( Bendall, MJ, 1984) |
| "Norfloxacin has a well proven efficacy in UTI but remains to be proven in enteric infections." | 2.37 | Principles for targeted antibiotic use in urinary tract and enteric infections: a review with special emphasis on norfloxacin. ( Norrby, SR, 1986) |
| " Urine samples were taken every 2 h during the whole dosing interval of the particular antibiotic." | 1.33 | Urinary bactericidal activity of oral antibiotics against common urinary tract pathogens in an ex vivo model. ( Bedenic, B; Bubonja, M; Budimir, A; Topic, M, 2006) |
| "Ten patients with clinical symptoms of benign prostatic hyperplasia undergoing TUR-P received 200 mg of both drugs per os simultaneously 2 hours before surgery." | 1.31 | Comparison of ofloxacin and norfloxacin concentration in prostatic tissues in patients undergoing transurethral resection of the prostate. ( Chen, J; Chen, RR; Huang, HS, 2001) |
| "Treatment with pivalic acid containing prodrugs has been shown to cause carnitine depletion by loss of pivaloyl carnitine in urine." | 1.29 | Effect of short-term treatment with pivalic acid containing antibiotics on serum carnitine concentration--a risk irrespective of age. ( Abrahamsson, K; Holme, E; Jodal, U; Lindstedt, S; Nordin, I, 1995) |
| " Pharmacokinetic parameters for these dosage groups were as follows: Tmax values were 3." | 1.28 | [Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ( Aramaki, M; Kawakami, A; Koga, T; Motohiro, T; Oda, K; Oki, S; Sasaki, H; Shimada, Y; Tsumura, N; Yoshinaga, Y, 1990) |
| " They were given orally dosage ranging 5." | 1.28 | [Clinical study on norfloxacin in children]. ( Kagami, S; Okada, K, 1990) |
| "Norfloxacin was more active than the other agents against all gram-negative organisms tested." | 1.27 | Comparative in vitro activity of norfloxacin against urinary tract pathogens. ( Haase, D; Harding, G; Ronald, A; Urias, B, 1983) |
| "Norfloxacin (MK-0366) is a new antibacterial agent, closely related to nalidixic acid, with broad spectrum activity against Gram-positive and Gram-negative organisms, including Pseudomonas aeruginosa." | 1.27 | Norfloxacin (MK-0366) treatment of urinary tract infections in hospitalized patients. ( Panichi, G; Pantosti, A; Testore, GP, 1983) |
| "Norfloxacin was the most active antimicrobial agent tested against all isolates studied; it was the only agent active against P." | 1.27 | Comparative in vitro activities of norfloxacin (MK-0366) and six commonly used antimicrobial agents against 199 urinary isolates showing various degrees of antibiotic resistance. ( Appleman, MD; Corigliano, BE; Heseltine, PN; Leedom, JM, 1984) |
| "Norfloxacin was the most active agent in the study on a weight-for-weight basis." | 1.27 | Norfloxacin: in vitro activity compared with that of seven other antibacterial agents against urinary tract pathogens. ( Dibb, WL; Digranes, A; Ostervold, B, 1984) |
| "Norfloxacin has a much wider spectrum than nalidixic acid which includes pseudomonas and Gram-positive cocci." | 1.27 | The antimicrobial spectrum of norfloxacin. ( Newsom, SW, 1984) |
| "were treated with norfloxacin and 16 (84%) responded to therapy." | 1.27 | The treatment of Pseudomonas aeruginosa urinary tract infections with norfloxacin. ( Emmanuel, FX; Leigh, DA, 1984) |
| "Ciprofloxacin was found to be the most active drug tested against all gram-negative organisms and streptococci, with the exception of Streptococcus faecalis and Streptococcus pneumoniae." | 1.27 | Comparative in vitro activity of five quinoline derivatives and five other antimicrobial agents used in oral therapy. ( Hoogkamp-Korstanje, JA, 1984) |
| "Nalidixic acid was found to be more active in acid conditions, particularly against staphylococci, Streptococcus faecalis and Ps." | 1.27 | Laboratory evaluation of enoxacin: comparison with norfloxacin and nalidixic acid. ( Cowlishaw, A; Eley, A; Greenwood, D; Slater, G; Teoh-Chan, CH, 1985) |
| "Ciprofloxacin was the most active agent." | 1.27 | In vitro activity of pefloxacin compared with five other quinolones on nalidixic acid-resistant proteae species. ( Allocati, N; Cellini, L; Di Girolamo, A; Piccolomini, R; Scazzocchio, F; Selan, L, 1988) |
| "Pefloxacin was highly active against Staphylococcus aureus (39 strains; MIC90 1." | 1.27 | Activity of pefloxacin and thirteen other antimicrobial agents in vitro against isolates from hospital and genitourinary infections. ( Duerden, BI; Geary, I; Jones, BM; Lee, ME, 1986) |
| "Norfloxacin treatment resulted in clinical cure or improvement in 84 percent of patients and eradicated the etiologic pathogen(s) 52 percent of the time." | 1.27 | Compassionate use of norfloxacin. ( Corrado, ML; Heseltine, PN, 1987) |
| "Norfloxacin was substantially more effective than trimethoprim-sulphamethoxazole in reducing the number of colony forming units from kidney homogenates when the test animals were diabetic." | 1.27 | Norfloxacin versus trimethoprim-sulphamethoxazole: efficacy in a model of ascending urinary tract infection in normal and streptozotocin-induced diabetic mice. ( Abruzzo, GK; Fromtling, RA; Gadebusch, HH; Gilfillan, EC; Pelak, BA, 1985) |
| "Pefloxacin was given as the single drug (except in one case) to twenty-seven patients with a variety of infections (bone and/or joint: 8; respiratory tract: 6; urinary tract: 5; bacteremia: 4; meninges: 3; other: 1)." | 1.27 | [Pefloxacin: clinical experience]. ( Bertrand, A; Janbon, F; Jonquet, O; Jourdan, J; Santoni, A, 1985) |
| "Norfloxacin was the most active antimicrobial agent tested against the gram-negative bacilli." | 1.26 | Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates. ( Gruninger, RP; Khan, MY; Klicker, RE; Nelson, SM, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 124 (50.61) | 18.7374 |
| 1990's | 79 (32.24) | 18.2507 |
| 2000's | 25 (10.20) | 29.6817 |
| 2010's | 14 (5.71) | 24.3611 |
| 2020's | 3 (1.22) | 2.80 |
| Authors | Studies |
|---|---|
| Blango, MG | 1 |
| Mulvey, MA | 1 |
| Arafa, SH | 1 |
| Alshehri, WA | 1 |
| Organji, SR | 1 |
| Elbanna, K | 1 |
| Obaid, NA | 1 |
| Aldosari, MS | 1 |
| Asiri, FH | 1 |
| Ahmad, I | 1 |
| Abulreesh, HH | 1 |
| Wang, J | 1 |
| Gagne, JJ | 1 |
| Kattinakere-Sreedhara, S | 1 |
| Fischer, MA | 1 |
| Bykov, K | 1 |
| Araújo, MRB | 1 |
| Sant'Anna, LO | 1 |
| Santos, NNCD | 1 |
| Seabra, LF | 1 |
| Santos, LSD | 1 |
| Naber, KG | 1 |
| Niggemann, H | 1 |
| Stein, G | 2 |
| Singh, N | 1 |
| Gandhi, S | 1 |
| McArthur, E | 1 |
| Moist, L | 1 |
| Jain, AK | 1 |
| Liu, AR | 1 |
| Sood, MM | 1 |
| Garg, AX | 1 |
| Vachhani, AV | 1 |
| Barvaliya, M | 1 |
| Naik, V | 1 |
| Jha, P | 1 |
| Tripathi, C | 1 |
| Rocha, RM | 1 |
| Zanni, PC | 1 |
| de Souza Bonfim-Mendonça, P | 1 |
| Gimenes, F | 1 |
| Alczuk, SS | 1 |
| Svidzinski, TI | 1 |
| Consolaro, ME | 1 |
| Themphachanal, M | 1 |
| Kongpheng, S | 1 |
| Rattanachuay, P | 1 |
| Khianngam, S | 1 |
| Singkhamanan, K | 1 |
| Sukhumungoon, P | 1 |
| Price, JR | 1 |
| Guran, LA | 1 |
| Gregory, WT | 1 |
| McDonagh, MS | 1 |
| Pham, JN | 1 |
| Chambers, I | 1 |
| Poirel, L | 1 |
| Nordmann, P | 1 |
| Bell, SM | 1 |
| Ljung, R | 1 |
| Reimers, A | 1 |
| Ericsson, O | 1 |
| Burström, B | 1 |
| Slovacek, L | 1 |
| Priester, P | 1 |
| Petera, J | 1 |
| Slanska, I | 1 |
| Kopecky, J | 1 |
| Rajendran, R | 1 |
| Sreekumar, S | 2 |
| Sudhakar, A | 1 |
| Slekovec, C | 1 |
| Leroy, J | 1 |
| Vernaz-Hegi, N | 1 |
| Faller, JP | 1 |
| Sekri, D | 1 |
| Hoen, B | 1 |
| Talon, D | 1 |
| Bertrand, X | 1 |
| Fallah, F | 1 |
| Karimi, A | 1 |
| Goudarzi, M | 1 |
| Shiva, F | 1 |
| Navidinia, M | 1 |
| Jahromi, MH | 1 |
| Sajadi Nia, RS | 1 |
| Schaeffer, AJ | 6 |
| Nicolle, LE | 4 |
| Madsen, KS | 1 |
| Debeeck, GO | 1 |
| Blochlinger, E | 1 |
| Borrild, N | 1 |
| Bru, JP | 1 |
| Mckinnon, C | 1 |
| O'Doherty, B | 1 |
| Spiegel, W | 1 |
| Van Balen, FA | 2 |
| Menday, P | 1 |
| Menday, AP | 1 |
| Ticea, C | 1 |
| Wright, JM | 1 |
| Komp Lindgren, P | 2 |
| Karlsson, A | 1 |
| Hughes, D | 2 |
| Barisić, Z | 1 |
| Babić-Erceg, A | 1 |
| Borzić, E | 1 |
| Zoranić, V | 1 |
| Kaliterna, V | 1 |
| Carev, M | 1 |
| Lobel, B | 1 |
| Park, JH | 1 |
| Cho, YW | 1 |
| Cho, YH | 1 |
| Choi, JM | 1 |
| Shin, HJ | 1 |
| Bae, YH | 1 |
| Chung, H | 1 |
| Jeong, SY | 1 |
| Kwon, IC | 1 |
| Koyle, MA | 1 |
| Barqawi, A | 1 |
| Wild, J | 1 |
| Passamaneck, M | 1 |
| Furness, PD | 1 |
| Skrbo, A | 1 |
| Selava, A | 1 |
| Zunić, L | 1 |
| Arredondo-García, JL | 1 |
| Figueroa-Damián, R | 1 |
| Rosas, A | 1 |
| Jáuregui, A | 1 |
| Corral, M | 1 |
| Costa, A | 1 |
| Merlos, RM | 1 |
| Ríos-Fabra, A | 1 |
| Amábile-Cuevas, CF | 1 |
| Hernández-Oliva, GM | 1 |
| Olguín, J | 1 |
| Cardeñosa-Guerra, O | 1 |
| Marcusson, LL | 1 |
| Sandvang, D | 1 |
| Frimodt-Møller, N | 1 |
| Wilson, L | 1 |
| Ryan, J | 2 |
| Thelning, C | 1 |
| Masters, J | 1 |
| Tuckey, J | 1 |
| Norinder, BS | 1 |
| Norrby, R | 1 |
| Palmgren, AC | 1 |
| Hollenberg, S | 1 |
| Eriksson, U | 1 |
| Nord, CE | 3 |
| Bedenic, B | 1 |
| Topic, M | 1 |
| Budimir, A | 1 |
| Bubonja, M | 1 |
| Vedel, G | 1 |
| Toussaint, G | 1 |
| Riegel, P | 1 |
| Fouilladieu, JL | 1 |
| Billöet, A | 1 |
| Poyart, C | 1 |
| Papp, M | 1 |
| Farkas, A | 1 |
| Udvardy, M | 1 |
| Tornai, I | 1 |
| Siracusano, S | 1 |
| Knez, R | 1 |
| Tiberio, A | 1 |
| Alfano, V | 1 |
| Giannantoni, A | 1 |
| Pappagallo, G | 1 |
| Downs, J | 1 |
| Andriole, VT | 1 |
| Ryan, JL | 1 |
| Khan, MY | 1 |
| Gruninger, RP | 1 |
| Nelson, SM | 1 |
| Klicker, RE | 1 |
| Sweet, RL | 1 |
| Ohm-Smith, MJ | 1 |
| Hadley, WK | 1 |
| Bailey, RR | 2 |
| Peddie, BA | 1 |
| Blake, E | 1 |
| Jensen, KM | 1 |
| Madsen, PO | 1 |
| Norrby, SR | 3 |
| Haase, D | 1 |
| Urias, B | 3 |
| Harding, G | 1 |
| Ronald, A | 1 |
| Guerra, JG | 1 |
| Falconi, E | 1 |
| Palomino, JC | 1 |
| Benavente, L | 1 |
| Antunez de Mayolo, E | 1 |
| Giamarellou, H | 1 |
| Tsagarakis, J | 1 |
| Petrikkos, G | 1 |
| Daikos, GK | 1 |
| Panichi, G | 1 |
| Pantosti, A | 1 |
| Testore, GP | 1 |
| Deaney, NB | 4 |
| Vogel, R | 3 |
| Vandenburg, MJ | 2 |
| Currie, WJ | 2 |
| Corigliano, BE | 1 |
| Appleman, MD | 1 |
| Heseltine, PN | 2 |
| Leedom, JM | 1 |
| Greenwood, D | 2 |
| Osman, M | 1 |
| Goodwin, J | 1 |
| Cowlishaw, WA | 1 |
| Slack, R | 1 |
| Digranes, A | 1 |
| Dibb, WL | 1 |
| Ostervold, B | 1 |
| Kirby, CP | 1 |
| Round, EM | 2 |
| Newsom, SW | 3 |
| Bendall, MJ | 1 |
| Leigh, DA | 2 |
| Smith, EC | 1 |
| Marriner, J | 1 |
| Emmanuel, FX | 1 |
| Watt, B | 1 |
| Chait, I | 1 |
| Kelsey, MC | 1 |
| Newsom, RA | 1 |
| Smith, J | 1 |
| Toase, PD | 1 |
| Reeves, DS | 2 |
| Lacey, RW | 1 |
| Mummery, RV | 1 |
| Mahendra, M | 1 |
| Bint, AJ | 1 |
| Hoogkamp-Korstanje, JA | 1 |
| Haase, DA | 2 |
| Harding, GK | 4 |
| Thomson, MJ | 2 |
| Kennedy, JK | 2 |
| Urias, BA | 1 |
| Ronald, AR | 4 |
| Piccolomini, R | 2 |
| Allocati, N | 2 |
| Catamo, G | 1 |
| Esposito, S | 3 |
| Galante, D | 3 |
| Pennucci, C | 2 |
| Barba, D | 2 |
| Limauro, D | 1 |
| Scioli, C | 1 |
| Hirai, K | 3 |
| Ito, A | 1 |
| Abe, Y | 1 |
| Suzue, S | 2 |
| Irikura, T | 2 |
| Inoue, M | 2 |
| Mitsuhashi, S | 4 |
| Abrahamsson, K | 1 |
| Holme, E | 1 |
| Jodal, U | 1 |
| Lindstedt, S | 1 |
| Nordin, I | 1 |
| Rutschmann, OT | 1 |
| Zwahlen, A | 1 |
| Soussy, CJ | 2 |
| Delavault, P | 1 |
| Terry, JB | 1 |
| Hestin, D | 1 |
| Hanesse, B | 1 |
| Frimat, L | 1 |
| Renaudin, JM | 1 |
| Netter, P | 1 |
| Kessler, M | 1 |
| Fernández Fernández, A | 1 |
| Lantero Benedito, M | 1 |
| Gastañares Hernando, MJ | 1 |
| Undabeitia Santisteban, E | 1 |
| Fernández Santos, F | 1 |
| Castaño Rodríguez, A | 1 |
| Gil Fabra, J | 1 |
| Martínez Castellanos, F | 1 |
| Otero Mauricio, G | 1 |
| Yoshida, T | 1 |
| Muratani, T | 1 |
| Iyobe, S | 1 |
| Pfau, A | 2 |
| Sacks, TG | 2 |
| Pérez-Trallero, E | 1 |
| Urbieta, M | 1 |
| Jimenez, D | 1 |
| García-Arenzana, JM | 1 |
| Cilla, G | 1 |
| Davoren, P | 1 |
| Mainstone, K | 1 |
| DuBois, J | 1 |
| Martel, AY | 1 |
| Shafran, SD | 1 |
| Conly, JM | 1 |
| Hoepelman, IM | 1 |
| Havinga, WH | 1 |
| Benne, RA | 1 |
| Zwinkels, M | 1 |
| de Wit, MA | 1 |
| de Hond, HA | 1 |
| Boon, TA | 1 |
| Visser, MR | 1 |
| van Asbeck, FW | 1 |
| Verhoef, J | 1 |
| Pummer, K | 1 |
| Pittman, W | 1 |
| Moon, JO | 1 |
| Hamrick, LC | 1 |
| Cox, CE | 5 |
| Clark, J | 1 |
| Childs, S | 1 |
| Pizzuti, D | 1 |
| Fredericks, J | 1 |
| St Clair, P | 1 |
| Childs, SJ | 2 |
| Fukuoka, Y | 1 |
| Ikeda, Y | 1 |
| Yamashiro, Y | 1 |
| Takahata, M | 1 |
| Todo, Y | 1 |
| Narita, H | 1 |
| Imperiale, TF | 1 |
| Esber, EJ | 1 |
| Trienekens, TA | 1 |
| London, NH | 1 |
| Houben, AW | 1 |
| De Jong, RA | 1 |
| Stobberingh, EE | 1 |
| Toba, K | 2 |
| Nagano, K | 1 |
| Liang, J | 1 |
| Ouchi, Y | 1 |
| Orimo, H | 2 |
| Pascual, J | 1 |
| Orofino, L | 1 |
| Hernández, E | 1 |
| Liaño, F | 1 |
| García-González, R | 1 |
| Ortunño, J | 1 |
| Koren, G | 1 |
| Truong, QC | 1 |
| Ouabdesselam, S | 1 |
| Hooper, DC | 2 |
| Moreau, NJ | 1 |
| Scaglione, F | 1 |
| Demartini, G | 1 |
| Cocuzza, C | 1 |
| Raschi, S | 1 |
| Cogo, R | 1 |
| Hanson, B | 1 |
| D'Hondt, A | 1 |
| Depierreux, M | 1 |
| Lustman, F | 1 |
| Guibert, J | 1 |
| Herman, H | 1 |
| Capron, MH | 1 |
| Mavromanolakis, E | 2 |
| Maraki, S | 2 |
| Samonis, G | 2 |
| Tselentis, Y | 2 |
| Cranidis, A | 2 |
| Lundborg, CS | 1 |
| Hensjö, LO | 1 |
| Gustafsson, LL | 1 |
| Sundman, K | 1 |
| Arneborn, P | 1 |
| Blad, L | 1 |
| Sjöberg, L | 1 |
| Vikerfors, T | 1 |
| Ozeki, S | 1 |
| Deguchi, T | 1 |
| Yasuda, M | 1 |
| Nakano, M | 1 |
| Kawamura, T | 1 |
| Nishino, Y | 1 |
| Kawada, Y | 1 |
| Levadoux, M | 1 |
| Carli, P | 1 |
| Gadea, JF | 1 |
| De Mauleon De Bruyere, P | 1 |
| Perre, C | 1 |
| García-Rodríguez, JA | 1 |
| Trujillano Martín, I | 1 |
| Baquero, F | 1 |
| Cisterna, R | 1 |
| Gobernado, M | 1 |
| Liñares, F | 1 |
| Martín-Luengo, F | 1 |
| Piédrola, G | 1 |
| Pimentel, FL | 1 |
| Dolgner, A | 1 |
| Guimarães, J | 1 |
| Quintas, M | 1 |
| Mário-Reis, J | 1 |
| Lucena, MI | 1 |
| Andrade, RJ | 1 |
| Sanchez-Martinez, H | 1 |
| Perez-Serrano, JM | 1 |
| Gomez-Outes, A | 1 |
| Caron, F | 1 |
| Stuppy, BA | 1 |
| Alaniz, C | 1 |
| Stumpf, JL | 1 |
| Townsend, KA | 1 |
| Goettsch, W | 1 |
| van Pelt, W | 1 |
| Nagelkerke, N | 1 |
| Hendrix, MG | 1 |
| Buiting, AG | 1 |
| Petit, PL | 1 |
| Sabbe, LJ | 1 |
| van Griethuysen, AJ | 1 |
| de Neeling, AJ | 1 |
| Cahen, P | 1 |
| Honderlick, P | 1 |
| Kundu, AK | 1 |
| Abell, S | 1 |
| Chapman, S | 1 |
| Nadin, L | 1 |
| Warren, R | 1 |
| Kontoyiannis, DP | 1 |
| Chen, J | 1 |
| Chen, RR | 1 |
| Huang, HS | 1 |
| García Bernal, G | 1 |
| Favà Aixendri, E | 1 |
| Rubio Carque, V | 1 |
| Luna Jarque, J | 1 |
| Auquer, F | 1 |
| Cordón, F | 1 |
| Gorina, E | 1 |
| Caballero, JC | 1 |
| Adalid, C | 1 |
| Batlle, J | 1 |
| Iravani, A | 2 |
| Neringer, R | 1 |
| Forsgren, A | 1 |
| Hansson, C | 1 |
| Ode, B | 1 |
| Anderson, RU | 1 |
| Cortés, R | 1 |
| Pascual, T | 1 |
| Lou Arnal, S | 1 |
| Orozco, F | 1 |
| Sunyer, L | 1 |
| Cutajar, CL | 1 |
| Saginur, R | 1 |
| Bischoff, W | 1 |
| Waites, KB | 1 |
| Canupp, KC | 1 |
| DeVivo, MJ | 1 |
| Harada, N | 1 |
| Inoue, G | 1 |
| Shimada, K | 1 |
| Saga, M | 1 |
| Sawada, T | 1 |
| Hoshino, T | 1 |
| Ohata, N | 1 |
| Andrews, JM | 1 |
| Wise, R | 1 |
| Zhang, YY | 1 |
| Zhun, BY | 1 |
| Jiang, SC | 1 |
| Mengesha, B | 1 |
| Brumfitt, W | 1 |
| Hamilton-Miller, JM | 1 |
| Smith, GW | 1 |
| al-Wali, W | 1 |
| de Jong, Z | 1 |
| Pontonnier, F | 1 |
| Plante, P | 1 |
| Raz, R | 1 |
| Boger, S | 1 |
| Sardaro, C | 1 |
| Gaeta, GB | 1 |
| Giusti, G | 1 |
| Basani, F | 1 |
| Goldstein, EJ | 6 |
| Ferraro, G | 1 |
| Ambrosi, G | 1 |
| Bucci, L | 1 |
| Palmieri, R | 1 |
| Palmieri, G | 1 |
| Jasovich, A | 1 |
| Vázquez, L | 1 |
| Cassetti, I | 1 |
| Barclay, C | 1 |
| Cavalli, NH | 1 |
| López Blanco, O | 1 |
| Stamboulian, D | 1 |
| Aragonés, E | 1 |
| Torres, M | 1 |
| Sarrà, N | 1 |
| Martí, R | 1 |
| Fujii, R | 1 |
| Meguro, H | 1 |
| Arimasu, O | 1 |
| Ushijima, K | 1 |
| Abe, T | 2 |
| Nakazawa, S | 1 |
| Sato, H | 1 |
| Narita, A | 1 |
| Niino, K | 1 |
| Ichihashi, H | 1 |
| Miano, L | 1 |
| Goldoni, S | 1 |
| Tubaro, A | 1 |
| Paradiso Galatioto, G | 1 |
| Gandolfi, P | 1 |
| Corrado, ML | 5 |
| Roylance, PJ | 1 |
| Struble, WE | 2 |
| Lancaster, MS | 1 |
| Hesney, M | 1 |
| Brown, KR | 1 |
| Eng, RH | 2 |
| Landes, R | 2 |
| Harrison, L | 2 |
| Bolding, OT | 1 |
| Jonsson, M | 1 |
| Englund, G | 1 |
| Nörgård, K | 1 |
| Motohiro, T | 1 |
| Yoshinaga, Y | 1 |
| Tsumura, N | 1 |
| Oki, S | 1 |
| Sasaki, H | 1 |
| Aramaki, M | 1 |
| Oda, K | 1 |
| Kawakami, A | 1 |
| Koga, T | 1 |
| Shimada, Y | 1 |
| Touw-Otten, FW | 1 |
| de Melker, RA | 1 |
| Reynaert, J | 1 |
| Van Eyck, D | 1 |
| Vandepitte, J | 1 |
| Boerema, JB | 6 |
| Willems, FT | 2 |
| Rauser, EH | 1 |
| Ariano, RE | 1 |
| Anderson, BA | 1 |
| Hernandez Poblete, G | 1 |
| Morales, JM | 1 |
| Prieto, C | 1 |
| Andrés, A | 1 |
| Ortuño, T | 1 |
| Rodicio, JL | 1 |
| Kunkel, MJ | 1 |
| Iannini, PB | 1 |
| Wells, G | 1 |
| Snow, R | 1 |
| Berman, S | 1 |
| Kuno, K | 1 |
| Ogawa, A | 1 |
| Nakao, Y | 1 |
| Hayakawa, F | 1 |
| Ando, Y | 1 |
| Kito, O | 1 |
| Ihara, T | 1 |
| Kawaguchi, H | 1 |
| Ito, M | 1 |
| Kamiya, H | 1 |
| Sakurai, M | 1 |
| Ishikawa, J | 1 |
| Matsuura, T | 2 |
| Nagai, H | 1 |
| Kida, K | 1 |
| Matsuda, H | 1 |
| Murase, M | 1 |
| Morita, H | 1 |
| Tomoda, T | 1 |
| Araki, K | 1 |
| Kurashige, T | 1 |
| Nishibayashi, Y | 1 |
| Matsumoto, K | 1 |
| Zushi, N | 1 |
| Okada, K | 1 |
| Kagami, S | 1 |
| Seidmon, EJ | 1 |
| Krisch, EB | 1 |
| Truant, AL | 1 |
| Amy, BG | 1 |
| Hurst, AT | 1 |
| McCabe, RE | 3 |
| Puppo, P | 1 |
| Germinale, F | 1 |
| De Rose, AF | 1 |
| Fujimaki, K | 1 |
| Fujii, T | 1 |
| Aoyama, H | 3 |
| Sato, K | 2 |
| Inoue, Y | 1 |
| Mladenov, D | 1 |
| Tsvetkov, M | 1 |
| Kumanov, Kh | 1 |
| Edlund, C | 2 |
| Cristiano, P | 1 |
| Morelli, G | 1 |
| Simioli, F | 1 |
| Iovene, MR | 1 |
| Della Vittoria Scarpati, M | 1 |
| Manguso, L | 1 |
| Obana, Y | 1 |
| Nishino, T | 1 |
| Thompson, M | 1 |
| Kennedy, J | 1 |
| Chan, MK | 2 |
| Wong, WT | 2 |
| Cheng, IK | 2 |
| Nakamura, S | 1 |
| Minami, A | 1 |
| Nakata, K | 1 |
| Kurobe, N | 1 |
| Kouno, K | 1 |
| Sakaguchi, Y | 1 |
| Kashimoto, S | 1 |
| Yoshida, H | 1 |
| Kojima, T | 1 |
| Ohue, T | 1 |
| Kato, T | 1 |
| Neu, HC | 2 |
| Wolfson, JS | 1 |
| von Summeren, TR | 1 |
| Hosaka, M | 1 |
| Oomori, Y | 1 |
| Niwata, Y | 1 |
| Ewer, TC | 1 |
| Gilchrist, NL | 1 |
| Aitken, JM | 1 |
| Sainsbury, R | 1 |
| Brettman, LR | 1 |
| Falck, L | 1 |
| Bucht, H | 1 |
| Stegmayr, B | 1 |
| Svärd, R | 2 |
| Sheehan, GJ | 1 |
| Hoban, DJ | 1 |
| Li, MK | 1 |
| Wong, WS | 1 |
| Yin, PD | 1 |
| Tungsanga, K | 1 |
| Chongthaleong, A | 1 |
| Udomsantisuk, N | 1 |
| Petcharabutr, OA | 1 |
| Sitprija, V | 1 |
| Wong, EC | 1 |
| Meyran, M | 1 |
| Thabaut, A | 1 |
| Olthof, BJ | 1 |
| van Saene, HK | 2 |
| Dawani, ML | 1 |
| Sheikh, MA | 1 |
| Naqvi, SA | 1 |
| Marty, N | 1 |
| Clave, D | 1 |
| Cancet, B | 1 |
| Henry-Ferry, S | 1 |
| Didier, J | 1 |
| Scheife, RT | 1 |
| Grad, C | 3 |
| Osman, LM | 1 |
| Sabbour, MS | 1 |
| el-Baz, F | 1 |
| Teoh-Chan, CH | 1 |
| Cowlishaw, A | 1 |
| Eley, A | 1 |
| Slater, G | 1 |
| Esko, E | 1 |
| Renkonen, OV | 1 |
| Sabbaj, J | 5 |
| Hoagland, VL | 2 |
| Shih, WJ | 1 |
| Alpert, ML | 2 |
| Ginsberg, BP | 1 |
| Modde, H | 1 |
| Borsa, F | 1 |
| Humbert, G | 1 |
| Hill, S | 1 |
| Yeates, M | 1 |
| Pathy, J | 1 |
| Morgan, JR | 1 |
| Surico, N | 1 |
| Tavassoli, K | 1 |
| MacGowan, AP | 1 |
| Greig, MA | 1 |
| Clarke, EA | 1 |
| White, LO | 1 |
| Cellini, L | 1 |
| Di Girolamo, A | 1 |
| Selan, L | 1 |
| Scazzocchio, F | 1 |
| Kelly, JG | 1 |
| Lavan, J | 1 |
| Noel, J | 1 |
| Rossi, L | 1 |
| Fontana, R | 1 |
| Meloni, GA | 1 |
| Lee, C | 1 |
| Najem, A | 1 |
| Ginsburg, BP | 1 |
| Kahn, RM | 1 |
| Cherubin, CE | 1 |
| Ramirez-Ronda, C | 1 |
| Colon, M | 1 |
| Saavedra, S | 1 |
| Stein, GE | 1 |
| Mummaw, N | 1 |
| Boyko, EJ | 1 |
| Reller, LB | 1 |
| Kurtz, TO | 1 |
| Miller, K | 1 |
| Rylander, M | 1 |
| Rugendorff, E | 1 |
| Haralambie, E | 1 |
| Modaï, J | 1 |
| Jones, BM | 1 |
| Geary, I | 1 |
| Lee, ME | 1 |
| Duerden, BI | 1 |
| Rugendorff, EW | 1 |
| Cook, T | 1 |
| de Vevey, P | 1 |
| Darioli, R | 1 |
| Bille, J | 1 |
| Glauser, MP | 1 |
| Di Veroli, C | 1 |
| Carlizzi, G | 1 |
| Xagoraris, V | 1 |
| Westenfelder, M | 1 |
| Vahlensieck, W | 1 |
| Reinhartz, U | 1 |
| Marble, DA | 1 |
| Bosso, JA | 1 |
| Del Favero, A | 1 |
| Frongillo, RF | 1 |
| Menichetti, F | 1 |
| Boldrini, F | 1 |
| Guerciolini, R | 1 |
| Pauluzzi, S | 1 |
| Pauwels, R | 1 |
| Scheepers, J | 1 |
| Crombach, W | 1 |
| Boelaert, J | 1 |
| de Jaegere, PP | 1 |
| Daneels, R | 1 |
| Schurgers, M | 1 |
| Gordts, B | 1 |
| van Landuyt, HW | 1 |
| Joost, J | 1 |
| Hébert, JP | 1 |
| Desnottes, JF | 1 |
| Diallo, N | 1 |
| Caillet, R | 1 |
| Cherubin, C | 1 |
| Stilwell, S | 1 |
| Wang, C | 1 |
| Corrado, M | 1 |
| Hoagland, V | 1 |
| Hanno, P | 1 |
| Cynamon, MH | 1 |
| Wilcox, GH | 1 |
| Fontana, G | 1 |
| Laudi, M | 1 |
| Carlone, NA | 2 |
| Savoia, D | 2 |
| Borsotto, M | 1 |
| Cuffini, AM | 1 |
| Karachalios, GN | 1 |
| Georgiopoulos, AN | 1 |
| Mascellino, MT | 1 |
| Lorenzi, A | 1 |
| Bonanni, M | 1 |
| Iegri, F | 1 |
| Román Pumar, JL | 1 |
| Angelini, A | 1 |
| Mariucci, A | 1 |
| Goracci, P | 1 |
| Murase, T | 1 |
| Mitsuya, H | 1 |
| Fukatsu, H | 1 |
| Yoshida, K | 1 |
| Natsume, H | 1 |
| Obata, K | 1 |
| Ohshima, S | 1 |
| Asaka, H | 1 |
| Kobayashi, M | 1 |
| Okamura, K | 1 |
| Tarantino, G | 1 |
| Cambri, S | 1 |
| Pannain, M | 1 |
| Bergeron, MG | 1 |
| Thabet, M | 1 |
| Roy, R | 1 |
| Lessard, C | 1 |
| Foucault, P | 1 |
| Ganguli, LA | 1 |
| Keaney, MG | 1 |
| Gould, LJ | 1 |
| Holmes, B | 1 |
| Brogden, RN | 1 |
| Richards, DM | 1 |
| Fromtling, RA | 1 |
| Abruzzo, GK | 1 |
| Gilfillan, EC | 1 |
| Pelak, BA | 1 |
| Gadebusch, HH | 1 |
| Mancini, C | 1 |
| Brenciaglia, MI | 1 |
| Ghezzi, MC | 1 |
| Giordano, A | 1 |
| Nazzari, C | 1 |
| Cipriani, P | 1 |
| Bertrand, A | 1 |
| Janbon, F | 1 |
| Jourdan, J | 1 |
| Jonquet, O | 1 |
| Santoni, A | 1 |
| Banya, Y | 1 |
| Funaki, H | 1 |
| Takagane, H | 1 |
| Tanji, S | 1 |
| Aoki, H | 1 |
| Kubo, T | 1 |
| Ohori, T | 1 |
| Fukuoka, H | 1 |
| Goto, A | 1 |
| Sasaki, S | 1 |
| Muzzonigro, G | 1 |
| Caraceni, E | 1 |
| Baldassari, M | 1 |
| Ippoliti, L | 1 |
| Polito, M | 1 |
| Kurita, T | 1 |
26 reviews available for norfloxacin and Urinary Tract Infections
| Article | Year |
|---|---|
Review of the literature and individual patients' data meta-analysis on efficacy and tolerance of nitroxoline in the treatment of uncomplicated urinary tract infections.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Child; Female; Humans; Male; Nitroquin | 2014 |
Nitrofurantoin vs other prophylactic agents in reducing recurrent urinary tract infections in adult women: a systematic review and meta-analysis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Cefaclor; Estriol; Female; Humans; Nit | 2016 |
The expanding role of fluoroquinolones.
Topics: Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Enoxacin; Fluoroquinolones; Ga | 2002 |
Short term therapy for uncomplicated urinary tract infection today. Clinical outcome upholds the theories.
Topics: Anti-Bacterial Agents; Bacterial Infections; Cephalexin; Clinical Trials as Topic; Dose-Response Rel | 2003 |
Pediatric urinary tract infections: the role of fluoroquinolones.
Topics: Age Factors; Child; Child, Preschool; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Administ | 2003 |
[Bacterial infections in liver cirrhosis].
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ascites; | 2007 |
A review of urinary tract infection in the elderly.
Topics: Aged; Anti-Infective Agents, Urinary; Bacteriuria; Drug Combinations; Female; Humans; Male; Middle A | 1984 |
Fluoroquinolones reviewed.
Topics: Adult; Anti-Infective Agents; Child; Ciprofloxacin; Clinical Trials as Topic; Female; Humans; Norflo | 1993 |
Norfloxacin-induced cholestatic jaundice.
Topics: Aged; Anti-Infective Agents; Cholestasis; Humans; Male; Norfloxacin; Urinary Tract Infections | 1998 |
[Current role of aminoglycosides in the treatment of acute pyelonephritis].
Topics: Acute Disease; Administration, Oral; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Cefadroxil | 1998 |
Antibiotic therapy for urinary tract infections.
Topics: Cefaclor; Cephalosporins; Clinical Trials as Topic; Europe; Female; Humans; Male; Norfloxacin; Unite | 1992 |
Prevention of bacterial resistance in urinary tract infections.
Topics: Drug Resistance, Microbial; Humans; Norfloxacin; Recurrence; Urinary Tract Infections | 1991 |
Review of norfloxacin in lower urinary tract infections.
Topics: Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Male; Norfloxacin; Urinary T | 1990 |
Review of norfloxacin in complicated and recurrent urinary tract infections.
Topics: Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Norfloxacin; Recurrence; Urinary Tract I | 1990 |
Clinical impact of newer quinolones: influence on normal microflora.
Topics: Bacterial Infections; Ciprofloxacin; Humans; Immune Tolerance; Intestinal Mucosa; Norfloxacin; Oroph | 1989 |
The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.
Topics: Anti-Bacterial Agents; Bacteria; Blood Proteins; Ciprofloxacin; Enoxacin; Fluorine; Humans; Kidney; | 1985 |
Urology update: focus on UTI. Structure--introduction.
Topics: Chemical Phenomena; Chemistry; Humans; Microbial Sensitivity Tests; Norfloxacin; Structure-Activity | 1988 |
Nosocomial infection: risks associated with short-term and long-term inpatient care.
Topics: Aged; Anti-Bacterial Agents; Cross Infection; Humans; Length of Stay; Norfloxacin; Urinary Tract Inf | 1988 |
Manipulation of the oropharyngeal and intestinal microflora by norfloxacin: microbiological and clinical aspects.
Topics: Bacteria; Bacterial Infections; Humans; Immune Tolerance; Intestines; Norfloxacin; Oropharynx; Urina | 1988 |
Norfloxacin: its potential in clinical practice.
Topics: Bacterial Infections; Diarrhea; Gonorrhea; Humans; Neutropenia; Norfloxacin; Travel; Urinary Tract I | 1987 |
Norfloxacin: a quinoline antibiotic.
Topics: Animals; Bacteria; Chemical Phenomena; Chemistry; Clinical Trials as Topic; Drug Resistance, Microbi | 1986 |
Principles for targeted antibiotic use in urinary tract and enteric infections: a review with special emphasis on norfloxacin.
Topics: Bacterial Infections; Drug Resistance, Microbial; Enteritis; Humans; Norfloxacin; Urinary Tract Infe | 1986 |
World-wide clinical experience with norfloxacin: efficacy and safety.
Topics: Acute Disease; Agranulocytosis; Bacterial Infections; Clinical Trials as Topic; Diarrhea; Gastroente | 1986 |
Therapeutic principles of antimicrobial therapy and new antimicrobial agents.
Topics: Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Chemical Phenomena; Chemistry; Drug Therapy, | 1986 |
The role of 4-quinolones in the treatment of infections.
Topics: Bacterial Infections; Ciprofloxacin; Humans; Kinetics; Norfloxacin; Ofloxacin; Oxazines; Urinary Tra | 1987 |
Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Topics: Antifungal Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Culture Media; Drug Resistance, Microbial | 1985 |
91 trials available for norfloxacin and Urinary Tract Infections
| Article | Year |
|---|---|
Effectiveness and tolerability of short course co-trimoxazole, norfloxacin and levofloxacin in bacteriological cure of uncomplicated urinary tract infection in outpatient setting. An open label, parallel group, randomized controlled trial.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Double-Blind Metho | 2015 |
Three days of pivmecillinam or norfloxacin for treatment of acute uncomplicated urinary infection in women.
Topics: Acute Disease; Adult; Aged; Amdinocillin Pivoxil; Anti-Infective Agents; Double-Blind Method; Female | 2002 |
Symptomatic vaginal candidiasis after pivmecillinam and norfloxacin treatment of acute uncomplicated lower urinary tract infection.
Topics: Adult; Amdinocillin Pivoxil; Candidiasis, Vulvovaginal; Double-Blind Method; Female; Humans; Middle | 2002 |
Comparison of short-term treatment regimen of ciprofloxacin versus long-term treatment regimens of trimethoprim/sulfamethoxazole or norfloxacin for uncomplicated lower urinary tract infections: a randomized, multicentre, open-label, prospective study.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Administration Schedule; Female; Humans; Latin America; N | 2004 |
Is antibiotic prophylaxis required for flexible cystoscopy? A truncated randomized double-blind controlled trial.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Bacteriuria; Cystoscopy; Double-Blind Method; Enteroc | 2005 |
Microflora changes with norfloxacin and pivmecillinam in women with recurrent urinary tract infection.
Topics: Adolescent; Adult; Amdinocillin Pivoxil; Bacteria; Double-Blind Method; Female; Humans; Middle Aged; | 2006 |
The usefulness of antibiotic prophylaxis in invasive urodynamics in postmenopausal female subjects.
Topics: Adult; Aged; Antibiotic Prophylaxis; Cystoscopy; Female; Humans; Middle Aged; Norfloxacin; Postmenop | 2008 |
Potential usefulness of norfloxacin in the treatment of urinary tract infections.
Topics: Anti-Infective Agents; Clinical Trials as Topic; Humans; Nalidixic Acid; Norfloxacin; Tissue Distrib | 1983 |
Clinical evaluation of norfloxacin versus cotrimoxazole in urinary tract infections.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Bacteria; Clinical T | 1983 |
Norfloxacin versus cotrimoxazole in the treatment of lower urinary tract infections.
Topics: Adult; Aged; Anti-Infective Agents; Anti-Infective Agents, Urinary; Clinical Trials as Topic; Drug C | 1983 |
Norfloxacin, amoxycillin, cotrimoxazole and nalidixic acid. A summary of 3-day and 7-day therapy studies in the treatment of urinary tract infections.
Topics: Amoxicillin; Anti-Infective Agents, Urinary; Bacteria; Drug Administration Schedule; Drug Combinatio | 1984 |
Comparative study using norfloxacin and amoxycillin in the treatment of complicated urinary tract infections in geriatric patients.
Topics: Aged; Amoxicillin; Anti-Infective Agents, Urinary; Cinoxacin; Enterobacteriaceae; Humans; Microbial | 1984 |
Norfloxacin versus cotrimoxazole in the treatment of uncomplicated urinary tract infections--a multi-centre trial.
Topics: Anti-Infective Agents, Urinary; Bacteriuria; Drug Combinations; Female; Humans; Male; Nalidixic Acid | 1984 |
Treatment of acute urinary infection by norfloxacin or nalidixic acid/citrate: a multi-centre comparative study.
Topics: Acute Disease; Adolescent; Adult; Anti-Infective Agents, Urinary; Citrates; Citric Acid; Clinical Tr | 1984 |
Comparative trial of norfloxacin and trimethoprim-sulfamethoxazole in the treatment of women with localized, acute, symptomatic urinary tract infections and antimicrobial effect on periurethral and fecal microflora.
Topics: Acute Disease; Adult; Aged; Anti-Infective Agents, Urinary; Bacteria; Drug Combinations; Feces; Fema | 1984 |
Use of norfloxacin for prevention of symptomatic urinary tract infection in chronically catheterized patients.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Bacterial Infections; Cross- | 1995 |
Effective postcoital quinolone prophylaxis of recurrent urinary tract infections in women.
Topics: Adult; Ciprofloxacin; Coitus; Female; Humans; Norfloxacin; Ofloxacin; Prospective Studies; Recurrenc | 1994 |
Treatment of acute uncomplicated urinary tract infections with 3 days of lomefloxacin compared with treatment with 3 days of norfloxacin.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Infective Agents; Canada; Double-Blind Method; Female; | 1993 |
Safety and efficacy of lomefloxacin versus norfloxacin in the treatment of complicated urinary tract infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Female; Fluoroquinolones; Humans; | 1993 |
Single dose quinolone treatment in acute uncomplicated urinary tract infection in women.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Ciprofloxacin; Female; Gram-Negative Bacterial Infect | 1993 |
Fleroxacin versus norfloxacin in the treatment of urinary tract infections: a multicenter, double-blind, prospective, randomized, comparative study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Fleroxacin; Humans; Male; M | 1993 |
Randomized double-blind trial of high- and low-dose fleroxacin versus norfloxacin for complicated urinary tract infection.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Fleroxacin; Humans; Male; Middle Aged; | 1993 |
Fleroxacin versus norfloxacin for oral treatment of serious urinary tract infections.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Flero | 1993 |
Treating acute urinary tract infections. An RCT of 3-day versus 7-day norfloxacin.
Topics: Absenteeism; Acute Disease; Adolescent; Adult; Aged; Double-Blind Method; Escherichia coli Infection | 1993 |
Clinical assessment of indices for the prognosis of urinary tract infection in elderly patients receiving prophylaxis with norfloxacin.
Topics: Aged; Anti-Infective Agents; Female; Humans; Lymphocyte Count; Norfloxacin; Prognosis; Serum Albumin | 1995 |
Efficacy and tolerability of brodimoprim od versus norfloxacin bid in the treatment of bacterial urinary tract infections.
Topics: Adult; Anti-Infective Agents; Clinical Trials, Phase III as Topic; Female; Folic Acid Antagonists; H | 1995 |
[Treatment of uncomplicated recurrent cystitis in women: lomefloxacin versus norfloxacin].
Topics: Adult; Anti-Infective Agents; Cystitis; Drug Administration Schedule; Female; Fluoroquinolones; Huma | 1997 |
Effect of norfloxacin, trimethoprim-sulfamethoxazole and nitrofurantoin on fecal flora of women with recurrent urinary tract infections.
Topics: Adult; Anti-Infective Agents, Urinary; Enterobacteriaceae; Enterococcus; Feces; Female; Humans; Midd | 1997 |
One bolus dose of gentamicin and early oral therapy versus cefotaxime and subsequent oral therapy in the treatment of febrile urinary tract infection.
Topics: Adult; Aged; Aged, 80 and over; Cefotaxime; Drug Therapy, Combination; Female; Fever; Gentamicins; H | 1997 |
Efficacy and safety of norfloxacin 800 mg once-daily versus norfloxacin 400 mg twice-daily in the treatment of uncomplicated urinary tract infections in women: a double-blind, randomized clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Dose-Response Relationship, Drug; | 1998 |
Efficacy and safety of self-start therapy in women with recurrent urinary tract infections.
Topics: Adult; Anti-Infective Agents; Cost-Benefit Analysis; Female; Follow-Up Studies; Humans; Norfloxacin; | 1999 |
[Urinary infections without complications: comparison of a treatment with norfloxacin for 7 days versus norfloxacin for 3 days].
Topics: Adult; Anti-Infective Agents; Drug Administration Schedule; Female; Humans; Norfloxacin; Single-Blin | 2002 |
Single-dose ciprofloxacin versus 3 days of norfloxacin in uncomplicated urinary tract infections in women.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Double-Blind Method; Female; Humans; | 2002 |
Efficacy of lomefloxacin as compared to norfloxacin in the treatment of uncomplicated urinary tract infections in adults.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Drug Administratio | 1992 |
Lomefloxacin versus norfloxacin in the treatment of uncomplicated urinary tract infections: three-day versus seven-day treatment. The South Swedish Lolex Study Group.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Double-Blind Method; Drug Administration Schedule; F | 1992 |
Efficacy and tolerability of norfloxacin vs. ciprofloxacin in complicated urinary tract infection.
Topics: Ciprofloxacin; Drug Administration Schedule; Escherichia coli Infections; Female; Humans; Male; Midd | 1992 |
[Single oral dose of phosphomycin trometamol versus pipemidic acid and norfloxacin in treating uncomplicated low-level urinary tract infections].
Topics: Administration, Oral; Adult; Aged; Drug Administration Schedule; Female; Fosfomycin; Humans; Middle | 1992 |
Norfloxacin prophylaxis for endoscopic urological surgery.
Topics: Administration, Oral; Bacteremia; Bacteriuria; Endoscopy; Female; Humans; Kidney Calculi; Male; Norf | 1992 |
Single-dose compared with 3-day norfloxacin treatment of uncomplicated urinary tract infection in women. Canadian Infectious Diseases Society Clinical Trials Study Group.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Double-Blind Method; Drug Administration | 1992 |
Oral temafloxacin compared to norfloxacin for the treatment of complicated urinary tract infections.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Double-Blin | 1991 |
Efficacy and tolerance of norfloxacin in treatment of complicated urinary tract infection in outpatients with neurogenic bladder secondary to spinal cord injury.
Topics: Adult; Bacterial Infections; Drug Administration Schedule; Drug Tolerance; Female; Humans; Male; Mic | 1991 |
[Long-term single dose chemoprophylaxis of recurrent urinary tract infection in elderly female subjects].
Topics: Aged; Aged, 80 and over; Female; Humans; Norfloxacin; Recurrence; Time Factors; Urinary Tract Infect | 1991 |
[Clinical evaluation of enoxacin].
Topics: Adult; Dysentery, Bacillary; Enoxacin; Female; Gram-Negative Bacterial Infections; Humans; Male; Mid | 1991 |
The efficacy of norfloxacin in the treatment of urinary tract infections in Tikure Anbessa Hospital, Addis Ababa, Ethiopia.
Topics: Adult; Aged; Ethiopia; Female; Hospitals, Urban; Humans; Male; Microbial Sensitivity Tests; Middle A | 1991 |
Comparative trial of norfloxacin and macrocrystalline nitrofurantoin (Macrodantin) in the prophylaxis of recurrent urinary tract infection in women.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; Middle Aged; Nitrofurantoin; Norfloxacin | 1991 |
Single-dose fosfomycin trometamol (Monuril) versus multiple-dose norfloxacin: results of a multicenter study in females with uncomplicated lower urinary tract infections.
Topics: Drug Evaluation; Female; Fosfomycin; Humans; Norfloxacin; Urinary Tract Infections | 1991 |
Long-term prophylaxis with norfloxacin versus nitrofurantoin in women with recurrent urinary tract infection.
Topics: Female; Humans; Middle Aged; Nitrofurantoin; Norfloxacin; Recurrence; Urinary Tract Infections | 1991 |
Cefodizime (HR221) versus norfloxacin for treatment of urinary tract infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cefotaxime; Drug Evaluation; Female; Humans; Injections, | 1991 |
Fosfomycin trometamol versus norfloxacin in the treatment of uncomplicated lower urinary tract infections of the elderly.
Topics: Aged; Drug Administration Schedule; Female; Fosfomycin; Humans; Male; Norfloxacin; Remission Inducti | 1990 |
[Evaluation of norfloxacin in the pediatric field. Pediatric Study Group for Norfloxacin].
Topics: Administration, Oral; Bacterial Infections; Campylobacter Infections; Child; Child, Preschool; Drug | 1990 |
Review of norfloxacin in lower urinary tract infections.
Topics: Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Male; Norfloxacin; Urinary T | 1990 |
Review of the efficacy of oral norfloxacin in pyelonephritis and nosocomial urinary tract infection.
Topics: Administration, Oral; Antibody-Coated Bacteria Test, Urinary; Clinical Trials as Topic; Cross Infect | 1990 |
Norfloxacin versus trimethoprim-sulfamethoxazole in the treatment of urinary tract infections.
Topics: Adult; Aged; Drug Resistance, Microbial; Female; Humans; Male; Middle Aged; Multicenter Studies as T | 1990 |
Norfloxacin vs. pivmecillinam in the treatment of uncomplicated lower urinary tract infections in hospitalized elderly patients.
Topics: Aged; Aged, 80 and over; Amdinocillin; Amdinocillin Pivoxil; Clinical Trials as Topic; Female; Human | 1990 |
Single-dose pefloxacin versus five-days treatment with norfloxacin in uncomplicated cystitis in women.
Topics: Adult; Cystitis; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Human | 1990 |
Single dose fosfomycin trometamol versus multiple dose norfloxacin over three days for uncomplicated UTI in general practice.
Topics: Adolescent; Adult; Aged; Cystitis; Drug Administration Schedule; Escherichia coli; Female; Fosfomyci | 1990 |
Fosfomycin trometamol in a single dose versus norfloxacin for seven days in the treatment of uncomplicated urinary infections in general practice.
Topics: Adolescent; Adult; Bacteriuria; Double-Blind Method; Drug Administration Schedule; Drug Tolerance; E | 1990 |
Treatment of recurrent urinary tract infection with norfloxacin versus trimethoprim-sulfamethoxazole.
Topics: Adult; Aged; Aged, 80 and over; Escherichia coli Infections; Female; Humans; Male; Middle Aged; Norf | 1990 |
[Aztreonam vs norfloxacin: a comparative study of the treatment of urinary tract infections in ambulatory and hospitalized patients].
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Aztreonam; Clinical Trials as Topic; Cystitis; F | 1989 |
[Comparative evaluation of norfloxacin and cinoxacin in the therapy of complicated infections of the urinary tract].
Topics: Bacteria; Bacteriuria; Cinoxacin; Clinical Trials as Topic; Drug Tolerance; Female; Humans; Male; Mi | 1989 |
Prospective, randomized, placebo-controlled trial of norfloxacin for the prophylaxis of recurrent urinary tract infection in women.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Microbial Sensitivity Tests; N | 1989 |
A double-blind controlled trial of norfloxacin versus cotrimoxazole in the treatment of urinary tract infections.
Topics: Adult; Anti-Infective Agents, Urinary; Bacterial Infections; Double-Blind Method; Female; Humans; Ma | 1989 |
Coordinated multicenter study of norfloxacin versus trimethoprim-sulfamethoxazole treatment of symptomatic urinary tract infections. The Urinary Tract Infection Study Group.
Topics: Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Fe | 1987 |
Double-blind comparison of 3-day versus 7-day treatment with norfloxacin in symptomatic urinary tract infections. The Inter-Nordic Urinary Tract Infection Study Group.
Topics: Bacteriuria; Double-Blind Method; Drug Administration Schedule; Female; Humans; Middle Aged; Norflox | 1988 |
Norfloxacin: a new quinolone. Committee on Antimicrobial Agents, Canadian Infectious Disease Society.
Topics: Chemical Phenomena; Chemistry; Clinical Trials as Topic; DNA; Humans; Norfloxacin; Urinary Tract Inf | 1988 |
Comparative study of norfloxacin and trimethoprim for the treatment of elderly patients with urinary tract infection.
Topics: Aged; Aged, 80 and over; Bacterial Infections; Bacteriuria; Clinical Trials as Topic; Enterobacteria | 1988 |
Double-blind, randomized comparison of 24 weeks of norfloxacin and 12 weeks of norfloxacin followed by 12 weeks of placebo in the therapy of complicated urinary tract infection.
Topics: Bacteriuria; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; Humans; No | 1988 |
Treatment of urinary tract infections in Hong Kong: a comparative study of norfloxacin and co-trimoxazole.
Topics: Adult; Bacterial Infections; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Drug | 1988 |
Norfloxacin versus co-trimoxazole for the treatment of upper urinary tract infections: a double blind trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Clinical Trials as Topic; Double-B | 1988 |
Clinical trial of norfloxacin in urinary tract infection.
Topics: Adult; Clinical Trials as Topic; Female; Humans; Male; Norfloxacin; Urinary Tract Infections | 1987 |
Norfloxacin vs best parenteral therapy in treatment of moderate to serious, multiply-resistant, nosocomial urinary tract infections: a pharmacoeconomic analysis.
Topics: Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Clinical Trials as Topic; Cost-Benefit Analys | 1988 |
Multiclinic comparative study of norfloxacin and trimethoprim-sulfamethoxazole for treatment of urinary tract infections.
Topics: Adult; Bacteria; Clinical Trials as Topic; Drug Combinations; Female; Humans; Male; Microbial Sensit | 1985 |
Norfloxacin versus trimethoprim-sulfamethoxazole in the therapy of uncomplicated, community-acquired urinary tract infections.
Topics: Adult; Drug Combinations; Female; Humans; Nalidixic Acid; Norfloxacin; Sulfamethoxazole; Trimethopri | 1985 |
A controlled trial of norfloxacin and amoxycillin in the treatment of uncomplicated urinary tract infection in the elderly.
Topics: Aged; Amoxicillin; Anti-Infective Agents, Urinary; Clinical Trials as Topic; Humans; Middle Aged; Na | 1985 |
Multiclinic study of norfloxacin for treatment of urinary tract infections.
Topics: Clinical Trials as Topic; Drug Resistance, Microbial; Female; Gram-Negative Bacteria; Gram-Positive | 1987 |
Oral norfloxacin versus parenteral treatment of nosocomial urinary tract infection.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Clinical Trials as Topic; Cr | 1987 |
Norfloxacin in the treatment of complicated and uncomplicated urinary tract infections. A comparative multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Drug Combinations; Female; Humans; Male; M | 1987 |
Norfloxacin in the treatment of urinary tract infections in men with and without identifiable urologic complications.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Clinical Trials as Topic; Humans; Male; Mic | 1987 |
Treatment of urinary tract infection with norfloxacin. Analysis of cost.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clinical Trials as Topic; Costs and Cost Anal | 1987 |
A multicenter comparative trial of three-day norfloxacin vs ten-day sulfamethoxazole and trimethoprim for the treatment of uncomplicated urinary tract infections.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Drug Administra | 1987 |
Norfloxacin versus co-trimoxazole for treatment of urinary tract infections in adults: microbiological results of a coordinated multicentre study.
Topics: Anti-Bacterial Agents; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Escherichia | 1987 |
Low-dose norfloxacin versus placebo for long-term prophylaxis of recurrent uncomplicated urinary tract infection.
Topics: Adult; Aged; Bacteria; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Microbial Sens | 1987 |
Open randomised comparison of ofloxacin and norfloxacin in the treatment of complicated urinary tract infections.
Topics: Adult; Anti-Infective Agents; Bacteriuria; Female; Humans; Male; Microbial Sensitivity Tests; Norflo | 1987 |
Norfloxacin versus co-trimoxazole in the treatment of recurring urinary tract infections in men.
Topics: Anti-Infective Agents, Urinary; Bacteria; Drug Combinations; Humans; Male; Microbial Sensitivity Tes | 1986 |
[Comparative study of the treatment of simple urinary infection with a single dose of norfloxacin versus cotrimoxazole].
Topics: Adolescent; Adult; Aged; Anti-Infective Agents, Urinary; Double-Blind Method; Drug Combinations; Dru | 1987 |
Norfloxacin: a quinoline antibiotic.
Topics: Animals; Bacteria; Chemical Phenomena; Chemistry; Clinical Trials as Topic; Drug Resistance, Microbi | 1986 |
Norfloxacin versus pipemidic acid in complicated urinary tract infections due to susceptible pathogens: a comparative clinical trial.
Topics: Clinical Trials as Topic; Drug Resistance, Microbial; Escherichia coli; Female; Humans; Klebsiella; | 1986 |
Norfloxacin versus parenteral therapy in the treatment of complicated urinary tract infections and resistant organisms.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Clinical Trials as Topic; Costs and Cost Analysi | 1986 |
World-wide clinical experience with norfloxacin: efficacy and safety.
Topics: Acute Disease; Agranulocytosis; Bacterial Infections; Clinical Trials as Topic; Diarrhea; Gastroente | 1986 |
Norfloxacin (Noroxin).
Topics: Adult; Clinical Trials as Topic; Humans; Kinetics; Microbial Sensitivity Tests; Norfloxacin; Urinary | 1987 |
Norfloxacin versus nalidixic acid in the treatment of urinary tract infections.
Topics: Adult; Aged; Bacterial Infections; Bacteriuria; Female; Humans; Male; Middle Aged; Nalidixic Acid; N | 1987 |
131 other studies available for norfloxacin and Urinary Tract Infections
| Article | Year |
|---|---|
Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Cell Membrane Permeability; Cells, Cultured; Drug Resistan | 2010 |
Antimicrobial Resistance, Virulence Factor-Encoding Genes, and Biofilm-Forming Ability of Community-Associated Uropathogenic
Topics: Agar; Ampicillin; Animals; Anti-Bacterial Agents; Biofilms; Drug Resistance, Bacterial; Ertapenem; E | 2022 |
Association between initiation of fluoroquinolones and hospital admission or emergency department visit for suicidality: population based cohort study.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Cohort Studies; Emergency Service, Hospit | 2022 |
Monitoring fluoroquinolone resistance among ESBL-positive and ESBL-negative Escherichia coli strains isolated from urinary tract infections: An alert for empirical treatment.
Topics: Anti-Bacterial Agents; beta-Lactamases; Ciprofloxacin; Community-Acquired Infections; Escherichia co | 2023 |
Diclofenac inferior to norfloxacin for symptom relief of lower UTIs.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Disease Progression; Fem | 2018 |
Kidney function and the use of nitrofurantoin to treat urinary tract infections in older women.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Ciprofl | 2015 |
Effect of norfloxacin therapy for acute, uncomplicated lower urinary tract infection on vaginal Candida prevalence.
Topics: Acute Disease; Adolescent; Adult; Anti-Bacterial Agents; Brazil; Candida; Candidiasis, Vulvovaginal; | 2016 |
MOLECULAR CHARACTERIZATION OF VIRULENCE AND ANTIMICROBIAL SUSCEPTIBILITY PROFILES OF UROPATHOGENIC ESCHERICHIA COLI FROM PATIENTS IN A TERTIARY HOSPITAL, SOUTHERN THAILAND.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacterial Toxins; beta-Lactamases; Ciprofloxacin; Drug Res | 2015 |
Detection of a plasmid-mediated inducible cephalosporinase DHA-1 from Escherichia coli.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Cephalosporinase; Disk Diffusion Antimicrobial Tests; Esch | 2010 |
Inequality in quality? Regional and educational differences in treatment with fluoroquinolone in urinary tract infection of 236,376 Swedish patients.
Topics: Adolescent; Adult; Age Distribution; Amdinocillin Pivoxil; Anti-Infective Agents, Urinary; Ciproflox | 2011 |
Tamoxifen/norfloxacin interaction leading to QT interval prolongation in a female patient with extracranial meningioma.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Agents, Hormonal; Drug Interactions; Female | 2011 |
Biodegradable tocopherol acetate as a drug carrier to prevent ureteral stent-associated infection.
Topics: Absorbable Implants; Anti-Infective Agents, Urinary; Bacterial Adhesion; Cross Infection; Drug Carri | 2011 |
Impact of a region wide antimicrobial stewardship guideline on urinary tract infection prescription patterns.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Attitude of Health Personnel; Drug Prescriptions; Dr | 2012 |
Determination of integron frequency by a polymerase chain reaction-restriction fragment length polymorphism method in multidrug-resistant Escherichia coli, which causes urinary tract infections.
Topics: Adult; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Escherichia coli Infections; Fem | 2012 |
Case report: prescribing caution. When a simple disease isn't so simple.
Topics: Adult; Anti-Infective Agents, Urinary; Contraindications; Drug Information Services; Drug Interactio | 2003 |
Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; DNA Topoisomerases, Type II; DNA, Bacte | 2003 |
Urinary tract infections in South Croatia: aetiology and antimicrobial resistance.
Topics: Amoxicillin; Anti-Bacterial Agents; Bacterial Infections; Ceftibuten; Cephalosporins; Clavulanic Aci | 2003 |
Norfloxacin-releasing urethral catheter for long-term catheterization.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Adhesion; Drug Delivery Systems; Microscopy, Electron, Sc | 2003 |
[Pharmacoeconomic evaluation of use of ciprofloxacin and norfloxacin with cost-benefit analysis].
Topics: Adult; Anti-Infective Agents; Bosnia and Herzegovina; Ciprofloxacin; Cost-Benefit Analysis; Humans; | 2003 |
Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections.
Topics: Animals; Anti-Infective Agents; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infec | 2005 |
Urinary bactericidal activity of oral antibiotics against common urinary tract pathogens in an ex vivo model.
Topics: Acetamides; Administration, Oral; Adult; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; | 2006 |
Corynebacterium pseudogenitalium urinary tract infection.
Topics: Anti-Bacterial Agents; Corynebacterium; Corynebacterium Infections; Humans; Male; Middle Aged; Norfl | 2006 |
In vitro activity of MK-0366 against clinical urinary pathogens including gentamicin-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Bacteria; Escherichia coli; Humans; Microbial | 1982 |
Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates.
Topics: Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Bacteria; Humans; Microbial Sensitivity Tests | 1982 |
Comparative in-vitro activity of norfloxacin and selected antimicrobial agents against urinary tract pathogens and Neisseria gonorrhoeae.
Topics: Anti-Infective Agents, Urinary; Bacteria; Humans; Microbial Sensitivity Tests; Nalidixic Acid; Neiss | 1982 |
Norfloxacin for the treatment of uncomplicated urinary tract infections.
Topics: Adult; Bacterial Infections; Drug Evaluation; Female; Humans; Nalidixic Acid; Norfloxacin; Urinary T | 1983 |
Distribution of quinoline carboxylic acid derivatives in the dog prostate.
Topics: 4-Quinolones; Administration, Oral; Animals; Anti-Infective Agents; Dogs; Drug Evaluation, Preclinic | 1983 |
Comparative in vitro activity of norfloxacin against urinary tract pathogens.
Topics: Anti-Bacterial Agents; Drug Evaluation, Preclinical; Gram-Negative Aerobic Bacteria; Gram-Negative A | 1983 |
Norfloxacin (MK-0366) treatment of urinary tract infections in hospitalized patients.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Humans; Middle Aged; Nalidixic Acid; Norfloxacin; Ur | 1983 |
Norfloxacin in acute urinary tract infections.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteria; Bacteriuria; Child; Female; | 1984 |
Comparative in vitro activities of norfloxacin (MK-0366) and six commonly used antimicrobial agents against 199 urinary isolates showing various degrees of antibiotic resistance.
Topics: Anti-Infective Agents, Urinary; Drug Resistance, Microbial; Escherichia coli Infections; Humans; In | 1984 |
Norfloxacin: activity against urinary tract pathogens and factors influencing the emergence of resistance.
Topics: Anti-Bacterial Agents; Bacteria; Drug Resistance, Microbial; Escherichia coli; Humans; Hydrogen-Ion | 1984 |
Norfloxacin: in vitro activity compared with that of seven other antibacterial agents against urinary tract pathogens.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Resistance, Microbial; Enterobacteriacea | 1984 |
Norfloxacin--a new quinolone for urinary infection.
Topics: Anti-Infective Agents, Urinary; Humans; Nalidixic Acid; Norfloxacin; Urinary Tract Infections | 1984 |
Treatment of simple urinary tract infections in general practice with a 3-day course of norfloxacin.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents, Urinary; Bacteriuria; Child; Drug Resistance, Microb | 1984 |
The antimicrobial spectrum of norfloxacin.
Topics: Anti-Infective Agents, Urinary; Bacteria; Drug Combinations; Humans; Microbial Sensitivity Tests; Na | 1984 |
The treatment of Pseudomonas aeruginosa urinary tract infections with norfloxacin.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Female; Humans; Male; Microbial Sensiti | 1984 |
Comparative in vitro activity of five quinoline derivatives and five other antimicrobial agents used in oral therapy.
Topics: Administration, Oral; Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Dose-Response Relationship, Dr | 1984 |
Study of the in vitro activity of norfloxacin and other drugs on amoxicillin-resistant uropathogenic isolates.
Topics: Amoxicillin; Anti-Infective Agents, Urinary; Bacteria; Humans; Microbial Sensitivity Tests; Nalidixi | 1984 |
Comparative in vitro activity of norfloxacin and four other chemotherapeutics against urinary gram-negative isolates.
Topics: Anti-Infective Agents, Urinary; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Nalidix | 1984 |
Comparative activities of AM-715 and pipemidic and nalidixic acids against experimentally induced systemic and urinary tract infections.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Mice; Nalidixic Acid; Nicotinic Acids; Norflox | 1981 |
Effect of short-term treatment with pivalic acid containing antibiotics on serum carnitine concentration--a risk irrespective of age.
Topics: Adolescent; Adult; Age Factors; Aged; Amdinocillin Pivoxil; Carnitine; Female; Humans; Male; Middle | 1995 |
[Must pefloxacin and norfloxacin be studied separately against bacteria isolated from urinary tract infections by the API-ATB method?].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Urinary; Bacteriological Techni | 1995 |
Norfloxacin induced arthralgia.
Topics: Aged; Arthralgia; Female; Humans; Norfloxacin; Urinary Tract Infections | 1995 |
Norfloxacin-induced nephrotic syndrome.
Topics: Female; Humans; Middle Aged; Nephrotic Syndrome; Norfloxacin; Urinary Tract Infections | 1995 |
[Quinolone-resistant Escherichia coli in the health area of a 650-bed hospital].
Topics: Catchment Area, Health; Ciprofloxacin; Drug Resistance, Microbial; Escherichia coli; Hospital Bed Ca | 1994 |
Mechanisms of high-level resistance to quinolones in urinary tract isolates of Pseudomonas aeruginosa.
Topics: Anti-Infective Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; DNA Gyrase; DNA Topois | 1994 |
Ten-year survey of quinolone resistance in Escherichia coli causing urinary tract infections.
Topics: Anti-Infective Agents; Ciprofloxacin; Data Collection; Drug Resistance, Microbial; Escherichia coli; | 1993 |
Norfloxacin-induced hepatitis.
Topics: Adult; Chemical and Drug Induced Liver Injury; Female; Humans; Norfloxacin; Urinary Tract Infections | 1993 |
In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Lung Diseases | 1993 |
Preventing infection in cirrhotics with gastrointestinal hemorrhage.
Topics: Bacteremia; Bacterial Infections; Biometry; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; No | 1993 |
Subacute thyroiditis in a renal allograft recipient.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Biopsy, Needle; Cyclosporine; Escherichia coli Infe | 1996 |
Use of the new quinolones during pregnancy.
Topics: Abnormalities, Drug-Induced; Anti-Infective Agents; Child, Preschool; Ciprofloxacin; Female; Follow- | 1996 |
Sequential mutations of gyrA in Escherichia coli associated with quinolone therapy.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Codon; DNA Gyrase; DNA Topoisomerases | 1995 |
Nephrotic syndrome after norfloxacin.
Topics: Aged; Amlodipine; Anti-Infective Agents; Antihypertensive Agents; Clonidine; Creatinine; Diuretics; | 1996 |
"Academic drug-detailing": from project to practice in a Swedish urban area.
Topics: Anti-Infective Agents; Drug Information Services; Family Practice; Feasibility Studies; Humans; Info | 1997 |
Development of a rapid assay for detecting gyrA mutations in Escherichia coli and determination of incidence of gyrA mutations in clinical strains isolated from patients with complicated urinary tract infections.
Topics: Anti-Infective Agents; Asparagine; Ciprofloxacin; DNA Gyrase; DNA Topoisomerases, Type II; DNA, Bact | 1997 |
[Repeated rupture of the extensor tendons of the hand due to fluoroquinolones. Apropos of a case].
Topics: Acute Disease; Aged; Anti-Infective Agents; Blood Vessels; Chronic Disease; Female; Hand; Hemosidero | 1997 |
In vitro activity of fosfomycin trometamol against pathogens from urinary tract infections: a Spanish multicenter study.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cephalosporins; Drug Resistance, Microbial; Drug Thera | 1997 |
The use of norfloxacin in a university hospital.
Topics: Cost Control; Drug Resistance, Microbial; Drug Utilization; Female; Hospital Bed Capacity, 500 and o | 1991 |
Increasing resistance to fluoroquinolones in escherichia coli from urinary tract infections in the netherlands.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Anti-Infective Agents, Urinary; Drug Resistance, Mic | 2000 |
[Nitrofurans: a modern treatment for uncomplicated urinary infections?].
Topics: Anti-Infective Agents, Urinary; Bacterial Infections; Drug Resistance, Microbial; Enterobacteriaceae | 2000 |
Norfloxacin-induced hallucination--an unusual CNS toxicity of 4-fluoroquinolones.
Topics: Adult; Anti-Infective Agents; Female; Hallucinations; Humans; India; Norfloxacin; Urinary Tract Infe | 2000 |
Seasonal variation in fluoroquinolone prescribing.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Utilization Review; England; Humans; Norfloxacin; Ofloxac | 1999 |
The impact of norfloxacin, ciprofloxacin and ofloxacin on human gut colonization by Candida albicans.
Topics: Adult; Aged; Anti-Infective Agents; Candida albicans; Ciprofloxacin; Digestive System; Female; Human | 2001 |
Comparison of ofloxacin and norfloxacin concentration in prostatic tissues in patients undergoing transurethral resection of the prostate.
Topics: Aged; Anti-Infective Agents; Humans; Male; Middle Aged; Norfloxacin; Ofloxacin; Postoperative Compli | 2001 |
Susceptibility testing of urinary tract pathogens to norfloxacin.
Topics: Bacteria; Enterobacteriaceae; Humans; Microbial Sensitivity Tests; Norfloxacin; Pseudomonas aerugino | 1991 |
[Analysis of urinary infection in the 1st month after kidney transplantation. Value of short prophylaxis with norfloxacin].
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Female; Humans; Kidney Transplantation; Male; Midd | 1990 |
[Single dose in therapeutic strategy in acute urinary tract infection].
Topics: Acute Disease; Amoxicillin; Anti-Bacterial Agents; Female; Humans; Norfloxacin; Time Factors; Trimet | 1990 |
[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field].
Topics: Age Factors; Child; Drug Evaluation; Drug Resistance, Microbial; Dysentery, Bacillary; Female; Human | 1990 |
Exacerbation of myasthenia gravis by norfloxacin.
Topics: Adult; Female; Humans; Myasthenia Gravis; Norfloxacin; Urinary Tract Infections | 1990 |
Usefulness of norfloxacine prophylaxis in late recurrent urinary tract infection after renal transplantation.
Topics: Humans; Kidney Transplantation; Norfloxacin; Prospective Studies; Urinary Tract Infections | 1990 |
Norfloxacin use in urinary tract infection by urologists and infectious disease specialists.
Topics: Administration, Oral; Adult; Aged; Drug Resistance, Microbial; Female; Humans; Male; Middle Aged; No | 1990 |
[Bacteriological and clinical studies on norfloxacin in the field of pediatrics].
Topics: Administration, Oral; Adolescent; Age Factors; Bacteria; Child; Child, Preschool; Drug Evaluation; D | 1990 |
[Clinical evaluation of norfloxacin in children].
Topics: Adolescent; Age Factors; Bacteria; Child; Child, Preschool; Drug Evaluation; Drug Resistance, Microb | 1990 |
[Clinical effect of norfloxacin in pediatric field].
Topics: Adolescent; Age Factors; Bacteria; Child; Child, Preschool; Colitis; Drug Evaluation; Drug Resistanc | 1990 |
[Clinical efficacy and safety of norfloxacin tablets in pediatrics].
Topics: Acute Disease; Administration, Oral; Adolescent; Age Factors; Bronchitis; Child; Child, Preschool; D | 1990 |
[Clinical study on norfloxacin in children].
Topics: Administration, Oral; Adolescent; Age Factors; Child; Child, Preschool; Drug Evaluation; Female; Hum | 1990 |
Quinolone resistance in clinical isolates of Serratia marcescens.
Topics: Anti-Infective Agents; Bacterial Outer Membrane Proteins; DNA Topoisomerases, Type II; Drug Resistan | 1989 |
[The treatment of urinary tract infections with nolitsin].
Topics: Adult; Aged; Bacterial Infections; Drug Evaluation; Female; Gram-Negative Bacteria; Gram-Positive Ba | 1989 |
In vivo activity of ciprofloxacin, ofloxacin, norfloxacin and pipemidic acid against Escherichia coli infections in mice.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Escherichia coli Infections; Female; Mice; Microbial | 1989 |
In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Enoxacin; Fluoroquino | 1989 |
Norfloxacin resistance in a clinical isolate of Escherichia coli.
Topics: DNA Topoisomerases, Type II; Drug Resistance, Microbial; Escherichia coli; Escherichia coli Infectio | 1987 |
Clinical use of the quinolones.
Topics: Anti-Infective Agents; Ciprofloxacin; Diarrhea; Enoxacin; Gastrointestinal Diseases; Humans; Naphthy | 1987 |
The in-vitro comparative activity of quinolones against bacteria from urinary tract infections in general practice.
Topics: Anti-Infective Agents, Urinary; Bacteria; Ciprofloxacin; Enterococcus faecalis; Escherichia coli; Hu | 1986 |
New 4-quinolones in the treatment of urinary tract infections.
Topics: Anti-Infective Agents, Urinary; Ciprofloxacin; Drug Combinations; Humans; Male; Norfloxacin; Pefloxa | 1986 |
In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Resistance, Micr | 1986 |
Suppressive therapy with norfloxacin in patients with recurrent and/or complicated urinary tract infection.
Topics: Escherichia coli Infections; Female; Humans; Male; Middle Aged; Norfloxacin; Recurrence; Time Factor | 1988 |
[In-vivo bacteriostatic and bactericidal activity of pefloxacine].
Topics: Blood Bactericidal Activity; Enterobacteriaceae; Humans; Norfloxacin; Pefloxacin; Pseudomonas aerugi | 1986 |
Effects of norfloxacin on the faecal flora in patients with complicated urinary tract infections.
Topics: Bacteria, Aerobic; Bacteria, Anaerobic; Candida; Enterobacteriaceae; Enterococcus faecalis; Feces; H | 1986 |
[Corynebacterium group D2. Clinical study, biochemical identification and antibiotic sensitivity].
Topics: Anti-Bacterial Agents; Ciprofloxacin; Corynebacterium; Corynebacterium Infections; Drug Resistance, | 1988 |
In vitro susceptibility of urinary pathogens to quinolones compared to other antimicrobial agents.
Topics: Anti-Bacterial Agents; Enterobacteriaceae; Humans; Microbial Sensitivity Tests; Norfloxacin; Ofloxac | 1987 |
Laboratory evaluation of enoxacin: comparison with norfloxacin and nalidixic acid.
Topics: Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Bacteria; Drug Evaluation; Enoxacin; Humans; | 1985 |
Comparative in vitro activity of norfloxacin and seven other antimicrobial agents against clinical isolates from urinary tract infections.
Topics: Anti-Infective Agents, Urinary; Cefaclor; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; | 1985 |
[Norfloxacin sensitivity of bacterial pathogens of urinary tract infections].
Topics: Anti-Infective Agents, Urinary; Bacterial Infections; Humans; Microbial Sensitivity Tests; Nalidixic | 1985 |
[Treatment of urinary tract infections].
Topics: Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Chlamydia Infections; Female; Humans; Lactams | 1985 |
Occurrence of gram negative bacteria in midstream bladder urine and their sensitivity to quinoline derivatives.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents, Urinary; Drug Resistance, Microbial; Female; Gram-Ne | 1985 |
[Etiopathogenetic interpretation of urinary tract infections associated with pelvic inflammatory disease and a clinico-therapeutic study of the effects of norfloxacin].
Topics: Adolescent; Bacteria; Female; Humans; Norfloxacin; Pelvic Inflammatory Disease; Urinary Tract Infect | 1988 |
The pharmacokinetics of norfloxacin in the aged.
Topics: Aged; Aged, 80 and over; Female; Half-Life; Humans; Male; Norfloxacin; Urinary Tract Infections | 1988 |
In vitro activity of pefloxacin compared with five other quinolones on nalidixic acid-resistant proteae species.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Microbial Sensitivity Tests; Nalid | 1988 |
Chronic dose urinary and serum pharmacokinetics of norfloxacin in the elderly.
Topics: Aged; Aged, 80 and over; Female; Half-Life; Humans; Norfloxacin; Urinary Tract Infections | 1988 |
In vitro testing of the antibacterial activity of fosfomycin trometamol against urinary pathogens.
Topics: Bacteria; Drug Combinations; Drug Resistance, Microbial; Fosfomycin; Humans; Microbial Sensitivity T | 1988 |
[Pefloxacin: evaluation and clinical prospects].
Topics: Bacterial Infections; Evaluation Studies as Topic; Female; Humans; Lung Diseases; Male; Meningitis; | 1986 |
Activity of pefloxacin and thirteen other antimicrobial agents in vitro against isolates from hospital and genitourinary infections.
Topics: Anti-Bacterial Agents; Bacteria; Bacteria, Anaerobic; Cross Infection; Humans; Microbial Sensitivity | 1986 |
Norfloxacin: targeted antibiotic therapy. Proceedings of a workshop. Taormina, Sicily, 11 April 1986.
Topics: Humans; Norfloxacin; Urinary Tract Infections | 1986 |
Norfloxacin treatment in complicated urinary tract infection.
Topics: Adolescent; Adult; Aged; Bacteriuria; Child; Enterobacteriaceae Infections; Female; Humans; Male; Mi | 1986 |
[Norfloxacin in chronic renal insufficiency].
Topics: Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Norfloxacin; Urinary Tract Infections | 1987 |
Patient compliance and efficacy of low-dose, long-term prophylaxis in patients with recurrent urinary tract infection.
Topics: Adult; Anti-Infective Agents; Child; Follow-Up Studies; Humans; Norfloxacin; Patient Compliance; Pyr | 1987 |
Efficacy and safety of pefloxacin in the treatment of patients with complicated urinary tract infections.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteria; Bacteriuria; Drug Evaluation; Escherichia | 1986 |
Case report of renal failure during norfloxacin therapy.
Topics: Acute Kidney Injury; Aged; Escherichia coli Infections; Female; Humans; Norfloxacin; Urinary Tract I | 1986 |
[Norfloxacin in the treatment of urinary tract infections].
Topics: Adolescent; Adult; Aged; Escherichia coli Infections; Female; Humans; Male; Middle Aged; Norfloxacin | 1986 |
[Effects of subinhibitory concentrations of pefloxacine on hemolysin production and adherence of urinary Escherichia coli].
Topics: Bacterial Adhesion; Bacterial Proteins; Child; Escherichia coli; Escherichia coli Proteins; Hemolysi | 1986 |
Treatment of urinary infections: clinical perspectives.
Topics: Adult; Aztreonam; Cinoxacin; Drug Resistance, Microbial; Escherichia coli; Female; Humans; Klebsiell | 1987 |
Effect of fosfomycin trometamol on bacterial adhesion in comparison with other chemotherapeutic agents.
Topics: Bacterial Adhesion; Drug Combinations; Escherichia coli; Fosfomycin; Hemagglutination; Humans; Micro | 1987 |
Norfloxacin: a fluoroquinolone carboxylic acid antimicrobial agent.
Topics: Humans; Norfloxacin; Urinary Tract Infections | 1987 |
Compassionate use of norfloxacin.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections | 1987 |
Antimicrobial activity of norfloxacin in enteric and urinary tract infections: combined effect of norfloxacin with aminoglycosides, tetracycline and chloramphenicol.
Topics: Acinetobacter; Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; Chloramphenicol; Drug C | 1986 |
[Study of a national survey to evaluate the in vitro activity of norfloxacin and 6 other antibiotics against urinary pathogens].
Topics: Anti-Bacterial Agents; Humans; Norfloxacin; Urinary Tract Infections | 1986 |
[Clinical experience with norfloxacin in urinary tract infections in gynecology].
Topics: Adolescent; Adult; Aged; Drug Evaluation; Female; Genital Diseases, Female; Humans; Middle Aged; Nor | 1986 |
[Clinical study of NFLX (norfloxacin) in complicated urinary tract infections].
Topics: Adult; Aged; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Middle Aged; Norfl | 1986 |
[Norfloxacin: hepatic tolerance].
Topics: Adult; Female; Humans; Liver; Liver Function Tests; Male; Middle Aged; Norfloxacin; Urinary Tract In | 1986 |
Norfloxacin penetration into human renal and prostatic tissues.
Topics: Aged; Humans; Kidney; Kidney Cortex; Kidney Medulla; Male; Middle Aged; Norfloxacin; Prostate; Urina | 1985 |
Norfloxacin: a three-day course for the treatment of urinary tract infection.
Topics: Adolescent; Adult; Aged; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Nausea; Nor | 1985 |
The in-vitro activity of EN 272, a quinolone-7-carboxylic acid, in comparison with other quinolones.
Topics: Anti-Bacterial Agents; Bacteria; Enoxacin; Humans; Microbial Sensitivity Tests; Nalidixic Acid; Naph | 1985 |
Norfloxacin versus trimethoprim-sulphamethoxazole: efficacy in a model of ascending urinary tract infection in normal and streptozotocin-induced diabetic mice.
Topics: Animals; Anti-Infective Agents; Diabetes Mellitus, Experimental; Disease Models, Animal; Drug Combin | 1985 |
[In vitro activity of norfloxacin against gram-positive and gram-negative organisms from recent clinical isolates].
Topics: Escherichia coli; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Test | 1985 |
[Pefloxacin: clinical experience].
Topics: Acinetobacter Infections; Adult; Aged; Bacterial Infections; Enterobacteriaceae Infections; Enteroco | 1985 |
[Clinical experience of norfloxacin in urinary tract infection].
Topics: Adolescent; Adult; Aged; Bacteria; Drug Evaluation; Drug Resistance, Microbial; Female; Humans; Midd | 1985 |
[Clinical experience of norfloxacin (Baccidal) in the urological field].
Topics: Adult; Aged; Bacteria; Cystitis; Drug Evaluation; Drug Resistance, Microbial; Female; Humans; Middle | 1985 |
Norfloxacin treatment in urinary tract infections by urease-producing bacteria accompanying renal calculi. Our experience.
Topics: Adult; Female; Humans; Kidney Calculi; Male; Middle Aged; Norfloxacin; Proteus; Proteus Infections; | 1985 |
[Clinical studies of norfloxacin in urinary tract infections].
Topics: Adult; Aged; Cystitis; Drug Evaluation; Drug Resistance, Microbial; Enterobacteriaceae; Female; Huma | 1985 |